

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/16176 A2

- (51) International Patent Classification⁷: C07K 14/47 (74) Agent: STERNAGEL, FLEISCHER, GODEMEYER & PARTNER; Braunsberger Feld 29, D-51429 Bergisch Gladbach (DE).
- (21) International Application Number: PCT/EP00/08071
- (22) International Filing Date: 18 August 2000 (18.08.2000) (81) Designated States (*national*): CA, JP, US.
- (25) Filing Language: English (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (26) Publication Language: English
- (30) Priority Data:
99116766.9 30 August 1999 (30.08.1999) EP
- Published:
— Without international search report and to be republished upon receipt of that report.
- (71) Applicant (*for all designated States except US*): BIOFRONTERA PHARMACEUTICALS GMBH [DE/DE]; Hemmelrather Weg 201, D-51377 Leverkusen (DE).
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): LÜBBERT, Hermann [DE/DE]; Höhenstrasse 59, D-51381 Leverkusen (DE).



WO 01/16176 A2

(54) Title: TRANSGENIC ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES

(57) Abstract: The present application refers to a mouse parkin2 DNA- and protein sequence, containing mutations or deletions causing Parkinson's disease in a human if occurring in the according human sequence, the construction of a transgenic non-human animal containing such a mutated DNA sequence and therefore expressing no or a less active or non-active parkin protein as well as the use of this transgenic animal as a model for neurodegenerative diseases.

Transgenic animal model for neurodegenerative diseases

The present invention relates to a mouse parkin2 DNA- and protein sequence containing naturally occurring or artificially introduced mutations or deletions, which cause Parkinson's disease in a human if they occur in the
5 according human sequence, the construction of a truncated parkin gene, which expresses no, a non-active or a truncated parkin protein and a model of a transgenic animal, expressing such a less or non-active parkin protein instead of the native parkin protein or no parkin protein, as well
10 as to the use of such a transgenic animal as a model for neurodegenerative diseases, preferred Parkinson's disease.

Neurodegenerative disorders are some of the most feared illnesses in society. During the last 10 years some of the genetic causes of many of
15 the primary neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease and several ataxic syndromes, have been identified. These findings gave new insights in the knowledge about the initiating trigger as well as the resulting consequences of those diseases. Due to the fact that
20 these diseases have many pathological mechanisms in common it seems possible that only relatively few pathways to neuronal death are involved in these disorders. Thus, treatment strategies for a particular neurodegenerative disease may be found to have value in other related disorders.

25

Parkinson's disease is a progressive neurodegenerative movement disorder with severe symptoms like rigidity, bradykinesia or tremor. The disease symptoms appear after degeneration of more than 70-80% of dopaminergic neurons. Broadly speaking the disease falls into two categories, namely
30 late onset and early onset. Late onset, which occurs in older age (55+ years), mainly as consequence of environmental influences, leads to

enhanced dopaminergic neuron death at a faster rate and to a more severe degree than normal. Early onset Parkinson's disease is much more infrequent but starts between the ages of 35 and 60 years. There is evidence that three forms of this early type of Parkinson's disease show a
5 tendency to run in families and is therefore known as familial Parkinson's disease.

In both the early and late onset types of Parkinson's disease, the pathology is the same but the abnormalities tend to be more severe and
10 more widespread in cases beginning at an earlier age. The disease is characterised by lesions in brain areas where the cell bodies of the dopaminergic neurons are located mainly in the substantia nigra compacta. In addition intracytoplasmic inclusions known as Lewy bodies can be observed in different brain regions, in particular in substantia nigra and
15 the locus ceruleus.

Recently two loci could be identified associated with early onset PD, one on human chromosome 4q21-23 ("PARK 1" gene locus) with a gene defect to be due to a missense mutation in the α -synuclein protein (or *parkin1*), a
20 small abundant brain molecule (Polymeropoulos, M. *et al.*, Science 1997; 276:2045-2047), and one on chromosome 2p13 ("PARK 3" gene locus)(Gasser, T. *et al.*, Nat. Genet. 1998; 18: 262-265). Both forms are inherited in an autosomal dominant manner.

25 Lately an autosomal recessive form of familial Parkinson's disease could be observed, linked to human chromosome 6q25.2-27 ("PARK 2" gene locus) (Matsumine, H. *et al.*, Am J Hum Genet (1997); 60: 588-596). This gene, designated *parkin* (or later *parkin2*) contains 12 exons spanning more than 500 kb and encodes a protein of 465 amino acids (molecular weight 51,652
30 Dalton) with homology to ubiquitin at the N-terminal portion and a RING-finger like motif at the C-terminal portion.

It has been shown, that mutations in the α -synuclein gene lead to autosomal dominant Parkinson's disease (Polymeropoulos, M. *et al.*, Science 1997; 276: 2045-2047), as well as mutations in the parkin gene cause autosomal recessive juvenile parkinsonism (Kitada, T. *et al.*, Nature 5 1998; 392: 605-608; Hattori, N. *et al.*, Biochem Biophys Res Comm 1998; 249: 754-758)).

Further Hattori, N. *et al.*, have been shown in Ann Neurol 1998; 44: 935-941, that different deletions in the parkin gene are the reason for 10 truncated parkin proteins, causing autosomal recessive juvenile parkinsonism. Especially intragenic deletional mutations, involving exons 3 to 4, exon 3, exon 4 and exon 5, as well as exon 3 through exon 7 are described as effecting the disease. Deletion of exon 3 of the parkin gene is furthermore described by Lücking, C. *et al.* in the Lancet 1998; 352: 15 1355-1356 to cause autosomal recessive juvenile parkinsonism. Investigations of Abbas, N. *et al.* Human Molecular Genetics 1999; 8: 567-574 and Kitada, T. *et al.*, Nature 1998; 392: 805-808 show that mutations in the ubiquitin-like N-terminal part (exon 2) of the parkin gene can also cause autosomal recessive juvenile parkinsonism, as well as different 20 frameshift- or missense mutations.

Leroy, E. *et al.*, demonstrated in Hum Genet 1998; 103: 424-427 that deletions of exons 5, 6 and 7 of the human parkin gene leads to early onset Parkinson's disease.

25

At present most common therapies are dealing with the increase of dopamine content in PD patients via application of L-dopa as precursor of dopamine, dopamine agonists or MAO-B (Monoamino Oxidase B) inhibitors, e.g. Deprenyl, by blocking the degradation of dopamine. There are no prophylac- 30 tic therapies available to stop the progression of the degenerative disease before onset of symptoms in late onset PD. This is due to the fact that at present diagnosis is only possible when first symptoms occur. So

far it is not clear to which extent genetic components enhance the environmental components responsible for the increased cell death of dopaminergic neurons.

- 5 Although different transgenic animal models for neurodegenerative diseases like Alzheimer's disease have been created, a transgenic animal model for Parkinson's disease has not yet been described.

Homologous recombination may be employed for inactivation or alteration of
10 genes in a site-directed manner. A number of papers describe the use of homologous recombination in mammalian cells, including human cells. Illustrative of these papers are Kucherlapati *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:3153-3157; Kucherlapati *et al.* (1985) *Mol. Cell. Bio.* 5:714-720; Smithies *et al.* (1985) *Nature* 317:230-234; Wake *et al.* (1985)
15 *Mol. Cell. Bio.* 8:2080-2089; Ayares *et al.* (1985) *Genetics* 111:375-388; Ayares *et al.* (1986) *Mol. Cell. Bio.* 7:1656-1662; Song *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:6820-6824; Thomas *et al.* (1986) *Cell* 44:419-428; Thomas and Capecchi (1987) *Cell* 51:503-512; Nandi *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:3845-3849; and Mansour *et al.* (1988) *Nature*
20 336:348-352. Various aspects of using homologous recombination to create specific genetic mutations in embryonic stem cells and to transfer these mutations to the germline have been described (Evans and Kaufman (1981) *Nature* 294:154-146; Dotschman *et al.*, (1987) *Nature* 330:576-578; Thomas and Capecchi (1987) *Cell* 51:503-512; Thompson *et al.* (1989) *Cell* 56:316-
25 321. The combination of a mutant polyoma enhancer and a thymidine kinase promoter to drive the neomycin gene has been shown to be active in both embryonic stem cells and EC cells by Thomas and Capecchi, *supra*, 1987; Nicholas and Berg (1983) in *Teratocarcinoma Stem Cell*, eds. Siver, martin and Strikland (Cold Spring Harbor Lab., Cold Spring Harbor, N.Y. (pp. 469-
30 497); and Linney and Donerly, *Cell* 35:693-699, 1983.

The object of the present application is to provide the suppositions for a test model for neurodegenerative diseases, preferably Parkinson's disease and a valuable tool in the diagnosis and treatment of these conditions, as well as the development of experimental models of Parkinson's disease that
5 can be used to define further the underlying biochemical events involved in the pathogenesis of this disease.

This object is met by a polynucleotide sequence encoding a mouse parkin2 protein, containing naturally occurring or artificially introduced
10 mutations or deletions, which cause Parkinson's disease in a human if they occur in the according human sequence, a vector, containing such a sequence, a prokaryotic or eukaryotic cell, containing such a vector and a transgenic non-human animal, whose one or both alleles of a gene encoding a parkin gene are mutated in a way, that a protein with modified,
15 preferred less activity or no active protein is expressed.

The transgenic non-human animals according to the present invention can be used as models for analysing the symptoms of neurodegenerative diseases or as a model system for testing the efficacy of a treatment for a neuro-
20 degenerative disease, whereby it is not an object of the present application to provide any method for treating one of the described diseases in a human or animal.

Such models could presumably be employed, in one application, to screen
25 for agents that alter the degenerative course of Parkinson's disease. For example, a model system of Parkinson's disease could be used to screen for environmental factors that induce or accelerate the pathogenesis. Further an experimental model could be used to screen for agents that inhibit, prevent, or reverse the progression of Parkinson's disease. Presumably,
30 such models could be employed to develop pharmaceuticals that are effective in preventing, arresting, or reversing Parkinson's disease. Further such models can be used for examination of behaviour during the

development of a neurodegenerative disease, for examination of physiological and molecular biological correlation of the disease, for studies of drug effects and for determination of effective drug doses and toxicity. These applications should be considered as examples and should not limit the application of the models in any way.

The present invention provides model systems of neurodegenerative diseases, preferred Parkinson's disease, wherein the model system comprises a mutated isoform or a fragment of the mouse parkin2 gene (further designated as *mPark2*), a DNA sequence derived from SEQ ID NO: 1 encoding a mouse parkin2 protein corresponding to the human parkin protein encoded by human chromosome gene region 6q25.2-27 ("PARK 2" gene locus). Preferred the model system contains a mutated *mPark2* sequence or a *mPark2* sequence containing any deletion, coding for a mutated or truncated, less active or non-active parkin protein.

The sequence of human α -synuclein (*parkin1*) gene, as well as human parkin (*parkin2*) gene is known. Human parkin2 gene (further designated as *hPark2*) contains 12 exons, coding for a protein which has in full length 465 amino acids and a molecular weight of 51,652 Daltons.

The present application shows the full length cDNA of *mPark2* in SEQ ID NO:1, consisting of 12 exons, containing the full length open reading frame for the mouse parkin2 protein (SEQ ID NO:4) which coding region consists of 1395 bp, coding for a protein of 464 amino acids with a calculated molecular weight of 51615 Dalton. Further two shorter cDNAs spanning a coding region of 789 bp (SEQ ID NO: 2 (isolated from mouse brain cDNA library by specific PCR)) and 753 bp (SEQ ID NO: 3 (isolated from mouse kidney cDNA library by specific PCR)) corresponding to amino acid sequences of 262 amino acids (SEQ ID NO:5) and 250 amino acids (SEQ ID NO:6) respectively are provided.

During the work of isolation and sequencing of the sequences SEQ ID NO: 1 to 3 shown in this application Shimizu, N. *et al.* submitted a mouse parkin DNA sequence to the EMBL GenBank database, published in July 1999 with the accession number AB019558. The protein sequence of the mouse parkin
5 protein encoded by the published sequence is identical to SEQ ID No: 4.

The present invention refers to polynucleic acid sequences derived from SEQ ID NO: 1, containing naturally occurring or artificially introduced mutations or deletions, which are known to cause Parkinson's disease in a
10 human if they occur in the according human sequence.

The present invention encompasses further polynucleotide sequences containing naturally occurring mutations according to the wobble principle, which represents the degeneration of the genetical code, as
15 well as according to the polymorphism of the genetical code, encoding any protein which has the same or a homologous amino acid sequence as any of the mutated or truncated mouse parkin2 proteins of the present invention.

"Homologous amino acid sequence" in content with the mouse parkin2 protein
20 means in the present application an amino acid sequence, wherein at least 70 %, preferably 80 %, more preferably 90 % of the amino acids are identical to one of the proteins of the present invention and wherein the replaced amino acids preferably are replaced by homologous amino acids. As "homologous" amino acids are designated which have similar features
25 concerning hydrophobicity, charge, steric features etc. Most preferred are amino acid sequences, containing the species-dependent differences of the mouse amino acid sequence compared to human parkin protein shown in the alignment Figure No. 1. The alignment of the corresponding polynucleotide sequences with the exon boundaries is shown in Figure No. 2.

In the whole application for nucleotides and amino acids the usual designations (one-letter or three-letter code) are used, known by any person skilled in the art.

- 5 The full length polynucleotide sequence of SEQ ID NO:1 or fragments thereof can be obtained by isolation of genomic DNA, containing exons and introns of the mPark2 gene, by RNA transcripts of the DNA or by the preparation of cDNA, containing only the exons of the mPark2 gene. Further the full length sequence as well as fragments thereof may be obtained by
10 synthetical polymerisation of nucleotides.

A preferred polynucleotide sequence of the present application is a polynucleotide sequence derived from SEQ ID NO: 1, which is either mutated or in which parts of the sequence are deleted. Mutations, insertions or
15 deletions may be located 5'upstream of the open reading frame (i.e. in the promotor-region), or they can concern one or more exons of the open reading frame. More preferred is a sequence, containing either a mutated full length sequence or fragments of SEQ ID NO:1, encoding a truncated parkin2 protein (i.e. by mutations leading to a STOP codon or by
20 deletions) or no protein (i.e. if the mutation or deletion is located in the promotor-region in exon 1).

More preferred mutations or deletions concern either exon 1, wherein the promotor region is contained, or exon 3 and/or one or more of the other
25 exons.

Most preferred the polynucleotide sequence of the present application is selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID
30 NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17; SEQ ID NO: 18, SEQ ID NO:19 or SEQ ID NO:20 (see also Table 1 and 2).

One of the polynucleotide sequences SEQ ID NO:1 to 3 may be treated *in vitro* or *in vivo* by random or site-directed mutagenesis, by random or site-directed digestion, by recombination or fusion or any other method known of persons skilled in the art to obtain sequences derived from SEQ
5 ID NO:1 containing mutations or deletions leading to a less active or to no parkin protein. Of course a person skilled in the art will understand that the present invention encompasses as well any construction in which parts of or the whole polynucleotide sequence encoding the parkin gene is deleted or replaced by another sequence (i.e. by a sequence encoding an
10 antibioticum-resistance).

To obtain at least a transgenic non-human animal as a model for neurodegenerative diseases, the natural occurring sequence of the parkin gene in this animal may be replaced on one or both alleles of the
15 chromosomes by a sequence of mPark2, containing mutations or deletions according to the present invention. These animals produce either less or less active or no parkin protein.

The transgenic animals of the present invention are created using targeted
20 gene replacement, a sequence by which a specific DNA sequence of interest (target DNA) is replaced by an altered DNA (replacement DNA). The genome of embryonic stem (ES) cells is modified using homologous recombination (Capecchi, Science 1989; 244:1288 and U.S. Pat. No. 5,487,992). The embryonic stem cells are injected in blastocysts as an early state of the
25 developing embryo. The blastocysts are then placed in a pseudopregnant female animal.

Briefly, a vector is constructed that carries the replacement DNA. Both ends of the replacement DNA are flanked by long DNA sequences homologous
30 to the sequences flanking the target DNA. When the vector is introduced into ES cells, the homologous sequences align and recombination may take place. This results in the target DNA being exchanged for the replacement

DNA. The vector is not replicated in the cells and will be lost. The frequency of homologous recombination is low; thus, a screening system is used. The replacement DNA will contain a positive marker sequence, usually a neomycin resistance gene. Thus, any cells that incorporate the

5 replacement DNA by homologous recombination will resist neomycin. By growing cells in medium containing the drug neomycin one can select only those cells containing the replacement DNA. The ES cells containing the replacement DNA are then inserted into recipient mouse blastocysts to create chimeric mice. Chimeras with germ cells derived from the altered ES

10 cells transmit the modified genome to their offspring, yielding mice heterozygous for the target DNA (contain one target DNA and one replacement DNA). The heterozygotes are then bred with each other either to create mice homozygous for the replacement DNA and deficient in the target DNA or to maintain transgenic heterozygotes if the homozygotic mice

15 are not viable.

The DNA will comprise at least a portion of the gene(s) at the particular locus with introduction of a lesion into at least one, usually both copies, of the native gene(s), so as to prevent expression of a functional

20 parkin protein. The lesion may be an insertion, deletion, replacement or combination thereof. When the lesion is introduced into only one copy of the gene being inactivated, the (heterozygote) cells having a single unmutated copy of the target gene are amplified and may be subjected to a second transformation, where the lesion may be the same or different from

25 the first lesion, usually different, and where a deletion, or replacement is involved, may be overlapping at least a portion of the lesion originally introduced. The resulting transformants are screened for the absence of the functional protein of interest and the DNA of the cell may be further screened to ensure the absence of a wild-type target gene.

30 Alternatively, homozygosity as to a phenotype may be achieved by breeding hosts heterozygous for the mutation.

For the construction of a transgenic animal model according to the present application any suitable animal may be employed, however mammals are preferred. More preferred are rodents and most preferred are rats and mice.

5

In the following the single steps of creating the animal models will be described in detail.

Starting from a polynucleotide sequence encoding a parkin gene, preferably
10 from a sequence encoding a mPark2 gene, more preferably from a sequence according to any of SEQ ID NO:1 to 3, most preferred from SEQ ID NO: 1 a desired mutation, insertion or deletion is introduced to the sequence. Methods to create mutations by random or site-directed mutagenesis or desired insertions or deletions by random or site-directed digestion
15 and/or replacement are commonly known to persons skilled in the art and broadly described in the literature. The method how a mutation, insertion or deletion is introduced in the sequence is not relevant, however falls under the scope of the present invention, as long as any of the later described nucleotides, amino acids or sequences are involved.

20

The constructs may be modified to include functional entities other than the mutated sequence which may find use in the preparation of the construct, amplification, transformation of the host cell, and integration of the construct into the host cell.

25

The homologous sequence for targeting the construct may have one or more deletions, insertions, substitutions or combinations thereof. For example, the mPark2 gene may include a deletion at one site and an insertion at another site which includes a gene which may be used for selection, where
30 the presence of the inserted gene will result in a defective inactive protein product. Preferably, substitutions are employed. For an inserted gene, of particular interest is a gene which provides a marker, e.g.,

antibiotic resistance such as neomycin resistance, including G418 resistance.

- The deletion will be at least about 50 bp, or more usually at least about 100 bp, and generally not more than about 20 kbp, where the deletion will normally include at least a portion of the coding region including a portion of or one or more exons, a portion of one or more introns, and may or may not include a portion of the flanking non-coding regions, particularly the 5'-non-coding region (transcriptional regulatory region).
- Thus, the homologous region may extend beyond the coding region into the 5'-non-coding region or alternatively into the 3'-non-coding region. Insertions will generally not exceed 10 kbp, usually not exceed 5 kbp, generally being at least 50 bp, more usually at least 200 bp.
- The homologous sequence should include at least about 100 bp, preferably at least about 150 bp, more preferably at least about 300 bp of the target sequence and generally not exceeding 20 kbp, usually not exceeding 10 kbp, preferably less than about a total of 5 kbp, usually having at least about 50 bp on opposite sides of the insertion and/or the deletion in order to provide for double crossover recombination.

- Upstream and/or downstream from the target gene construct may be a gene which provides a tool to select out primary random integration of the construct in the genome. For this purpose, the herpes simplex virus thymidine kinase gene may be employed, since the presence of the thymidine kinase gene may be detected by the use of nucleoside analogs, such as Gancyclovir or Acyclovir, for their cytotoxic effects on cells that contain a functional HSV-tk gene. The absence of sensitivity to these nucleoside analogs indicates that homologous recombination has occurred.

30

The presence of the marker gene inserted into the gene of interest establishes the integration of the target construct into the host genome.

However, DNA analysis might be required in order to establish whether homologous or non-homologous recombination occurred. This can be determined by employing probes for the insert and then sequencing the 5' and 3' regions flanking the insert for the presence of the gene of
5 interest extending beyond the flanking regions of the construct or identifying the presence of a deletion, when such deletion is introduced.

The polymerase chain reaction (PCR) may be used, with advantage in detecting the presence of homologous recombination (Kim and Smithies,
10 (1988) Nucleic Acid Res. 16:8887-8903; and Joyner et al (1989) Nature 338:153-156). Primers may be used which are complementary to a sequence within the construct, usually complementary to the selection marker gene, and complementary to a sequence outside the construct and at the target locus. In this way, one can only obtain DNA duplexes having both of the
15 primers present in the complementary chains in homologous recombination has occurred. By demonstrating the presence of the primer sequences or the expected size sequence, the occurrence of homologous recombination is supported. Any person skilled in the art knows how to determine the suitable PCR primers and conditions.

20

The construct may further include a replication system which is functional in the mammalian host cell. For the most part, these replication systems will involve viral replication systems, such as Simian Virus 40, Epstein-Barr virus, papilloma virus, adenovirus and the like.

25

Where a marker gene is involved, as an insert, and/or flanking gene, depending upon the nature of the gene, it may have the wild-type transcriptional regulatory regions, particularly the transcriptional initiation regulatory region or a different transcriptional initiation
30 region. Whenever a gene is from a host where the transcriptional initiation region is not recognized by the transcriptional machinery of the mammalian host cell, a different transcriptional initiation region

- will be required. This region may be constitutive or inducible, preferably inducible. A wide variety of transcriptional initiation regions have been isolated and used with different genes. Of particular interest as promoters are the promoters of metallothionein-I and II from a mammalian host, thymidine kinase, beta-actin, immunoglobulin promoter, human cytomegalovirus promoters, and SV40 promoters. In addition to the promoter, the wild-type enhancer may be present or an enhancer from a different gene may be joined to the promoter region.
- 10 The construct may further include a replication system for prokaryotes, particularly *E. coli*, for use in preparing the construct, cloning after each manipulation, allowing for analysis, such as restriction mapping or sequencing, followed by expansion of a clone and isolation of the plasmid for further manipulation. When necessary, a different marker may be
- 15 employed for detecting bacterial transformants.

Once the vector has been prepared, it may be further manipulated by deletion of the bacterial sequences as well as linearisation, where a short deletion may be provided in the homologous sequence, generally not exceeding about 500 bp, generally being from about 50 to 300 bp. The small deletion will generally be near one or other end of the targeted structural gene.

The construction of the desired polynucleotide sequence may be carried out in a cloning vector and linearised prior to the transfection of ES cells. A broad range of cloning vectors as well as vectors for the homologous recombination are commercially available and may be selected according to the desired construction.

30 Cloning vectors are usually replicated in prokaryotic cells, which renders the selection and multiplication of the desired construct. It is not

critical which prokaryotic organism is used, but usually E.coli or a yeast strain is preferred.

E. coli is one prokaryotic host useful particularly for cloning the DNA
5 sequences of the present invention. Other microbial hosts suitable for use
include bacilli, such as *Bacillus subtilis*, and other enterobacteriaceae,
such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In these
prokaryotic hosts, one can also make expression vectors, which will
typically contain expression control sequences compatible with the host
10 cell (e.g., an origin of replication). In addition, any number of a
variety of well-known promoters will be present, such as the lactose
promoter system, a tryptophan (*trp*) promoter system, a beta-lactamase
promoter system, or a promoter system from phage lambda. The promoters
will typically control expression, optionally with an operator sequence,
15 and have ribosome binding site sequences and the like, for initiating and
completing transcription and translation.

Other microbes, such as yeast, may also be used for expression.

Saccharomyces is a preferred host, with suitable vectors having expression
20 control sequences, such as promoters, including 3-phosphoglycerate kinase
or other glycolytic enzymes, and an origin of replication, termination
sequences and the like as desired.

Homologous recombination may be used to insert a mutant sequence into a
25 host genome at a specific site, for example, at a host parkin locus. In
one type of homologous recombination, one or more host sequence(s) are
replaced; for example, a host parkin allele (or portion thereof) is
replaced with a mutant parkin allele (or portion thereof). In addition to
such gene replacement methods, homologous recombination may be used to
30 target a mutant parkin allele to a specific site other than a host parkin
locus. Homologous recombination may be used to produce transgenic non-
human animals and/or cells that incorporate mutant parkin alleles.

Further to the above described techniques a step of expressing the treated sequence may be inserted in the expiration. Therefore the construct is (sub)cloned into any expression vector, which may be brought into a
5 suitable eukaryotic cell. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline resistance or hygromycin resistance, to permit detection and/or selection of those cells transformed with the
10 desired DNA sequences. Polynucleotides encoding a variant parkin2 polypeptide may include sequences that facilitate transcription (expression sequences) and translation of the coding sequences, such that the encoded polypeptide product is produced. Construction of such polynucleotides is well known in the art and is described further in
15 Maniatis et al. *Molecular Cloning: A Laboratory Manual*, 2nd Ed. (1989), Cold Spring Harbor, N.Y. For example, but not for limitation, such polynucleotides can include a promoter, a transcription termination site (polyadenylation site in eukaryotic expression hosts), a ribosome binding site, and, optionally, an enhancer for use in eukaryotic expression hosts,
20 and, optionally, sequences necessary for replication of a vector.

Any suitable eukaryotic cell may be used, but insect cells or mammalian cells as primary cells or immortalized cell lines are preferred.

25 A number of suitable host cell lines capable of secreting intact human proteins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, Jurkat cells, etc. Baculovirus expression systems are useful for high level expression of heterologous genes in eukaryotic cells. Knops *et al.* (1991) *J. Biol. Chem.*
30 266(11):7285. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al. (1986) *Immunol. Rev.* 89:49, and necessary

processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, and the like. The vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment, microinjection of DNA into the nucleus or electroporation may be used for other cellular hosts. (See, generally, Maniatis, et al. Molecular Cloning: A Laboratory Manual, 2nd. Ed. Cold Spring Harbor Press, (1989). The DNA may be single or double stranded, linear or circular, relaxed or supercoiled DNA. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology (1990) 185:527-537.

For the creation of an animal model according to the present invention each polynucleotide sequence can be used, containing mutations, insertions or deletions which are known to cause Parkinson's disease in a human, when they occur in the corresponding human sequence. Preferred polynucleotide sequences for the creation of an animal model according to the present invention are those which mutations are shown in table 2. More preferred are polynucleotide sequences containing mutations or deletions shown in table 1. The most preferred polynucleotide sequence for the construction of a transgenic animal of the present invention is SEQ ID NO: 7. Further enclosed to the present invention is an animal model wherein the parkin sequence is replaced by an according sequence of another mammal (i.e. by the human sequence, containing one of the mutations, insertions or deletions described in the present application) or by a sequence encoding a marker, i.e. an antibioticum.

Table 1: Mutations or deletions in mPark2 cDNA (SEQ ID NO:1)

Position in SEQ ID NO:1	Replacement (DNA)	Replacement (protein)	SEQ ID NO (DNA seq)	SEQ ID NO (prot seq)
NT 300-540	Exon3	Frameshift, Truncation	7	21
NT 300-659	Exon3-4	ORF, deletion of 121 aa	8	22
NT 300-996	Exon3-7	Frameshift, Truncation	9	23
NT 541-659	Exon 4	Frameshift, Truncation	10	24
NT 659-744	Exon 5	Frameshift, Truncation	11	25
NT 660-996	Exon 5-7	Frameshift, Truncation	12	26
NT 996-1208	Exon 8-9	Frameshift, Truncation	13	27
NT: 229-230 (aa 34)	deletion AG	Gln→Stop at aa 38, nonsense	14	28
NT: 282 (aa 52)	deletion A	Asn→Stop at aa 54, nonsense	15	29
NT: 350-351 (aa 74)	deletion AG	Arg→Stop at aa 78, nonsense	16	30
NT: 136-299	Exon 2	Frameshift, Truncation	17	31

aa = amino acid

NT = nucleotide

Table 2: Replaced amino acids in mPark2 cDNA (SEQ ID NO:1)

Position in SEQ ID NO:1	Replacement (DNA)	Replacement (protein)	SEQ ID NO (DNA seq)	SEQ ID NO (prot seq)
NT: 608	G→T,	Lys→Asn (aa 161)	18	32
NT: 1369	C→A,	Thr→Asn (aa 415)	19	33
NT: 1483	G→A,	Trp→Stop (aa 453)	20	34

aa = amino acid

5 NT = nucleotide

Once the construct has been prepared and manipulated, the DNA is isolated from the procaryotic host according to any method known in the art. Before the DNA construct is introduced into the target cells for homologous
10 recombination undesired sequences may be removed from the vector, e.g. the undesired bacterial sequences. As target cells an embryonic stem (ES) cell line may be used. As already indicated above for the expression system, any convenient technique for introducing the DNA into the target cells may be employed. After transformation of the target cells, many target cells
15 are selected by means of positive and/or negative markers, as previously indicated, neomycin resistance and Acyclovir or Gancyclovir resistance. Those cells which show the desired phenotype may then be further analyzed by restriction analysis, electrophoresis, Southern analysis, polymerase chain reaction or the like. By identifying fragments which show the
20 presence of the lesion(s) at the target gene site, one can identify cells in which homologous recombination has occurred to inactivate the target gene.

For embryonic stem cells, after mutation, the cells may be plated onto a
25 feeder layer in an appropriate medium, e.g., fetal bovine serum enhanced DMEM. Cells containing the construct may be detected by employing a selective medium and after sufficient time for colonies to grow, colonies

may be picked and analyzed for the occurrence of homologous recombination. As described previously, the polymerase chain reaction may be used, with primers within and without the construct sequence but at the target locus. Those colonies which show homologous recombination may then be used for
5 embryo manipulating by blastocyst injection. Blastocysts may be obtained from 4 to 6 week old superovulated females by flushing the uterus 3.5 days after ovulation. The embryonic stem cells may then be trypsinized and the modified cells added to a droplet containing the blastocysts. At least
10 embryonic stem cells may be injected into the blastocoel of the blastocyst. After injection, at least one and not more than about 15 of the blastocysts are returned to each uterine horn of pseudopregnant females. Alternatively, any of the common techniques, i.g. microinjection of the mutated gene, or a fragment thereof, into a one-cell embryo
15 followed by incubation in a foster mother can be used.

The pups will usually be born 16-18 days after introduction of the blastocysts into foster mothers. Chimeric animals will be mated with wild type (wt) mice to create heterozygote transgenics.

20

With these methods it is possible to obtain transgenic non-human animals, whose one or both alleles of a gene encoding a parkin gene are mutated in a way, that a parkin protein with modified, preferred less activity or no active parkin protein is expressed.

25

"Mutated" means in this content replacements, insertions or deletions of nucleotides or polynucleotide sequences.

In consequence of the mutated parkin gene these animals produce a mutated
30 or truncated parkin protein or no parkin protein. Preferred - if a parkin protein is expressed - the parkin protein expressed by the transgenic animal contains any of the mutations or deletions shown in table 1 and 2.

represented by any of the proteins with an amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 or naturally occurring or artificially introduced mutants with a homologous protein sequence or fragments thereof, particularly preferred a parkin protein with a sequence according to SEQ ID NO:21 is expressed.

The expression of one of these proteins or no parkin protein in the transgenic non-human animals causes these animals to display features of a neurodegenerative disease. These features can be manifested in developing physiological, biochemical or molecular biological modifications in e.g. cells, tissues, organs or neuronal structures.

In accordance with standard protocols, cultured eukaryotic cells, either primary cultures or immortalised cell lines, may be transfected, either transiently or stably, with a mutant or fragmented mPark2 allele so that the cultured eukaryotic cell expresses a mutant parkin2 polypeptide.

The present application further refers to cells, typically mammalian cells and preferably mammalian cells of the neural, glial, or astrocytic lineage, that have been transformed or transfected with any DNA sequence according to the present invention, as well as to any cells which have been derived from a transgenic non-human animal, whereby the cells express any of the mutated parkin2 proteins isoforms according to the present invention, preferred any of the isoforms shown in table 1 or 2 or fragments thereof, or they contain a parkin sequence which is mutated in a way that they don't express a parkin protein. The cells derived from the transgenic animals may be cultured as cell-lines or as primary cultures.

Once established, all such cell lines can be grown continuously in culture and may be used for a variety of in vitro experiments to study parkin expression and processing.

- 5 The present invention further refers to a method of producing transgenic non-human animals and transformed cells that contain any polynucleotide sequence encoding any mutant mouse parkin2 protein isoform according to the present invention, preferably such as shown in table 1 or 2 or naturally occurring or artificially introduced mutants or fragments
10 thereof.

Preferred the above described polynucleotide sequences, the proteins and amino acid sequences as well as the transgenic animal models and cell lines may be used for any method for analysing the symptoms of
15 neurodegenerative diseases.

Such neurodegenerative diseases encompass among others Parkinson's disease, Alzheimer's disease, Huntigton's disease, amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease, Pick's disease, Prion
20 disease, or second causes inducing Parkinson's syndromes like toxins (e.g. Mn, Fe, 6-hydroxydopamine, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), CO), drugs, brain tumors, head trauma, stroke, vascular irregularities, or metabolic irregularities.

- 25 Enclosed to these methods are methods outside of a living body, which are methods of molecular biology like PCR, Southern and Northern blot analysis, construction of DNA or RNA probes, as well as Western blot analysis, preparation of epitopes from the protein or amino acid sequences mentioned in this application, production of monoclonal and polyclonal
30 antibodies. These methods may be used for screening of samples, preferred of biological fluids for either the expression of parkin protein as a method for detecting the presence of the protein, or in a nucleic acid

sample or another sample removed from a subject, the presence of the gene for Parkinson's disease comprising identifying a genetic alteration in a gene sequence coding for parkin. Further enclosed are pathobiochemical, immunobiological and neurological as well as histochemical methods carried
5 out after sacrificing the animal for considering the effects of neurodegenerative diseases, particularly Parkinson's disease to the living body. Further methods for locating the presence of genetic alterations associated with Parkinson's disease are provided. These methods may be used outside of a living body to predict the development of the disease
10 prior to onset or for genetic screening.

However, particularly preferred is a method of testing the efficacy of a treatment for a neurodegenerative disease associated with a less active or non-active parkin protein, comprising subjecting any of the created
15 transgenic animals as a model to a putative treatment and determining the efficacy of said treatment.

These testing methods preferably comprise administering an active substance, whose effect can be determined by any of the above described
20 methods, to a transgenic animal according to the present invention.

By the use of the transgenic animals described in the present application it is possible the first time to test in a model system whether an active substance is useful for treating a condition associated with non-active
25 parkin protein and determining a level of the active substance, which causes an effect in treating the disease.

Treatments may carried out as single dose applications, but it is preferred to use the transgenic animals in long-time experiments with
30 multiple dose applications.

- The transgenic animals of the present application may be particularly used as model systems for screening for drugs and evaluating drug effectiveness. Additionally, such model systems provide a tool for defining the underlying biochemistry of neurodegenerative diseases, which thereby provides a basis for rational drug design. The models may be used further for studies of behaviour, physiological and molecular biological examinations, pharmacological and toxicological studies and several other applications.
- 10 Having detected the genetic mutation in the gene sequence coding for parkin protein in an individual not yet showing overt signs of Parkinson's disease, using any of the methods of the present invention, it may be possible to employ gene therapy, in the form of gene implants, to prevent the development of the disease.
- 15 Additional embodiments directed to modulation of the production of variant parkin proteins include methods that employ specific antisense polynucleotides complementary to all or part of a variant parkin sequence according to any of the sequences mentioned in this application, or for
- 20 some embodiments a wild-type parkin sequence. Such complementary antisense polynucleotides may include nucleotide substitutions, additions, deletions, or transpositions, so long as specific hybridisation to the relevant target sequence is retained as a property of the polynucleotide. Thus, an antisense polynucleotide must preferentially bind to a variant
- 25 parkin sequence as compared to a wild-type parkin. It is mostly preferred that the antisense polynucleotide reflects the exact nucleotide sequence of the variant allele (or wild-type allele where desired) and not a degenerate sequence.
- 30 Complementary antisense polynucleotides include soluble antisense RNA or DNA oligonucleotides which can hybridise specifically to a variant parkin mRNA species and prevent transcription of the mRNA species and/or

translation of the encoded polypeptide (Ching et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:10006; Broder et al. (1990) Ann. Int. Med. 113:604; Loreau et al. (1990) FEBS Letters 274:53-56); Holcenberg et al. WO91/11535; U.S. Pat. No. 7,530,165 ("New human CRIPTO gene"--publicly
5 available through Derwent Publications Ltd., Rochdale House, 128 Theobalds Road, London, UK); WO91/09865; WO91/04753; WO90/13641; and EP 386563, each of which is incorporated herein by reference). The antisense polynucleotides therefore inhibit production of the variant parkin polypeptides.

10

Antisense polynucleotides may be produced from a heterologous expression cassette in a transfectant cell or transgenic cell or animal, such as a transgenic neural, glial, or astrocytic cell, preferably where the expression cassette contains a sequence that promotes cell-type specific
15 expression (Wirak et al. loc. cit.). Alternatively, the antisense polynucleotides may comprise soluble oligonucleotides that are administered to the external milieu, either in the culture medium in vitro or in the circulatory system or interstitial fluid in vivo. Soluble antisense polynucleotides present in the external milieu have been shown
20 to gain access to the cytoplasm and inhibit translation of specific mRNA species. In some embodiments the antisense polynucleotides comprise methylphosphonate moieties. For general methods relating to antisense polynucleotides, see Antisense RNA and DNA, (1988), D. A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

25

Legends to the figures:

Figure 1 shows the alignment of the deduced amino acid sequences of the human and mouse Parkin2 protein (SEQ ID NO: 4).

30 Underlined are the conserved ubiquitin like (at the N-terminus) and Ring finger like (at the C-terminus) regions of both proteins.

Figure 2 shows the alignment of the nucleotide sequences of the human and mouse parkin 2 gene. Bold lines represent the exon boundaries identified for the human and mouse sequence.

- 5 Figure 3 represents a flow chart of the cloning procedure of the mouse parkin2 gene - exon3 knock-out construct.


Abbreviations:

a) Restriction endonucleases:

N = NotI, E= Eco RI, B= BamHI, H= HindIII, X= XbaI.

- 10 b) Modifications: ()= T4 DNA polymerase treatment in order to remove a restriction site in the resulting plasmid.

c)  pBluescript KSII (Stratagene) vector sequence

 = λ -Fix vector sequence

d) HSV-tk = herpes simplex promotor and thymidine kinase gene

- 15 e) kb = kilobases

The following examples are provided for illustration and are not intended to limit the invention to the specific example provided.

20 Example 1

Isolation of mouse Parkin2 cDNA clones:

- Arrayed mouse brain and mouse kidney cDNA libraries (Biofrontera
25 Pharmaceuticals/ Bio Systems) were screened by PCR under standard conditions using the primers Ex2s:*tcaggttcaactccagctatggc* and Ex2as:
tgcttgcgaaaatcacacgcagc . The cycle conditions were the following: 3 min.
95°C, (30sec. 95°C, 30sec. 56°C, 1min. 72°C) x 35 cycles.

Single colonies containing the mPark2 genes were verified by colony hybridisation according to the protocol described by Maniatis *et al.* 1989 (see above).

5 Construction of the Del Exon3 parkin gene (according to SEQ ID NO: 7)

All the further described cloning steps are shown in Figure 3. A genomic lambda ZIP clone (genomic mouse λ -Fix library, Stratagene) containing the exon 3 of the parkin gene was isolated by PCR using exon3 specific primer
10 of the mPark2 gene. A 3.1 kb BamHI/HindIII fragment of the lambda ZIP clone containing genomic DNA 3' end to the exon3 of mPark2 was cloned into the cloning vector pBluescript KS (Stratagene) to obtain the plasmid pmPark2-BH. Secondly, a 5 kb HindIII/EcoRI genomic DNA fragment was inserted into the HindIII site of the pmPark2-BH-clone. The EcoRI and
15 HindIII sites were destroyed by T4 DNA polymerase treatment. As result the plasmid pmPark2-BE- with a 8.1 kb long genomic region to the 3'-end of the exon 3 could be obtained.

A 2.0 kb XbaI/XhoI (the XbaI restriction site is located within the
20 multiple cloning sequence (mcs) of Lambda Fix) genomic DNA fragment containing the genomic region 5' to the exon3 was cloned into the EcoRI site of the pNeoloxp-vector (Giese *et al.* Science, 1998, 279:870-3) after generation of blunt ends by T4 DNA polymerase treatment. The BamHI-site (5'-to the EcoRI-site) of this vector was used subsequently for the
25 insertion of the 2.5 kb HSV-tk-marker gene. Again T4 DNA polymerase was used to generate blunt ends before ligation in order to eliminate the used cloning site. The resulting vector was digested with the restriction enzymes NotI and XhoI to obtain a 6.5 kb fragment containing the HSV-tk, the 2kb XhoI/XbaI genomic region to 5'-end of exon3, and the neo-marker.
30 The vector pmPark2-BE was digested with XhoI to linearise the plasmid. Both the isolated 6.5 kb fragment as well as the linear vector were

treated with T4 DNA polymerase prior to ligation to eliminate the used restriction sites.

This plasmid pmPark2del-ex3 was linearised with the restriction enzyme
5 NotI prior to transfection into ES cells.

Example 2

Transfection of ES cells:

10

Isolation and Freezing of the ES cells:

14 days old embryos were isolated, head and organs were removed from embryos, the remaining tissue was minced, and washed with 1x PBS. 1x trypsin (0.5g/l) / EDTA (0.2g/l) was used for dissolve the tissue by
15 incubating them at 37°C for 5 min. The reaction was stopped by adding 1 vol. EF medium (Embryonic Feeder medium: 1x DMEM, 10% FCS Serum, 2mM Glutamine, all obtained from LIFE Technologies), and cells were dissolved by pipetting several time up and down. The supernatant was centrifuged with 1000 rpm for 5 min. The fibroblasts from one embryo were seeded into
20 a 175 cm² flask with 30 ml medium. The medium was changed after 24 h. When the fibroblasts form a confluent monolayer they were splitted 1:3, and thereafter they were frozen when the cells are confluent again. Cells from 175 cm² flask were frozen into one tube. Therefore first empty tubes are place on ice, freezing medium is added (EF medium + 20% DMSO
25 (Dimethylsulfoxid)), cells with 0.5 ml EF medium are added, mixed, putted in a styrofoam box, which is cooled down in a -80°C freezer, and the next day the tubes are transferred into liquid N₂(l) tank.

Sub-culturing, inactivation and feeder layer:

30 The fibroblasts can be cultured on gelatine-coated plastic ware. The cells were splitted carefully 1:3 after 3 days. When feeder layer are needed for ES cell culturing, the fibroblasts should be division-inactivated by

mitomycin C. 2 mg mitomycin C are dissolved in 10 ml PBS, which can be stored at -20°C. This stock solution is diluted 1:20 with EF medium for inactivation; the nearly confluent fibroblasts in a 175 cm² flask are incubated in 20-30 ml of medium with mitomycin C for 2 h at 37°C.

- 5 Mitomycin C is then removed by 2x washing with PBS, and the inactivated fibroblasts are recovered in EF medium for 24 h before they are frozen or used for ES cell culturing after a few days. The cells are stored 37°C until they are used (maximally 10 days;) or they are frozen. For feeder layer, plate cells onto the same area; here the plastic ware has to be
10 coated by gelatine.

Sub-culturing the ES-cells:

- The ES cells were kept for 2-4 passages in culture. The medium is ES medium (1x DMEM, 15% FCS Serum, 2mM Glutamine, 1x nonessential amino
15 acids, 7µl β Mercaptoethanol, with supplement containing LIF (Leukemia Inhibitory Factor, 2.5x10⁵ to 10⁶ U/l), all obtained from LIFE Technologies), and the cells are splitted 1:6 every second day. Cells were refedded 2 h before passaging.

20 Stable Transfection of ES Cells

- After digestion of the gene targeting construct the DNA is extracted with phenol/CHCl₃ (24/23) and precipitated with EtOH (wash 2x with 75% EtOH); the rest of EtOH is removed carefully and air dried for approx. 15 min under steril conditions (laminar flow). The DNA is suspended in H₂O (final
25 conc.: 3 mg/ml). 5x10⁷ cells of a monolayer are treated with 1x trypsin to detach them from the ground of the flask, suspended in 0.8 ml medium and electroporated with DNA (30 µg linear DNA, 800 V, 3 µF, BioRad Gene Pulser). After 20 min at 4°C, cells are diluted with 9.5 ml medium and are plated onto dishes (9 cm diameter). 24 h after electroporation G418 (150-
30 175 mg /ml) is added to start selection. The medium is changed every day; after 7-9 days of selection colonies can be picked.

Picking colonies and culturing of picked colonies:

24 colonies were picked with Eppendorf tips under an inverted microscope. The colonies were transferred into the wells of a 96-well plate (round bottom), 30 μ l 1xtrypsin/EDTA are added, and the plates are incubated 10 min at 37°C. Thereafter 100 μ l ES-medium are added and the cells are suspended by pipetting up and down 12x with a multichannel pipette. The trypsinized cells are solitarily plated into a 24-well plate. The medium is exchanged every 24 h. 3-4 days after picking the cells are detached from the ground of the plates. Therefore the medium is removed, 60 μ l 1xtrypsin/EDTA are added and the plates are incubated for 7 min at 37°C. The treatment is stopped by adding 200 μ l medium and the cells are resuspended. 200 μ l of the cell suspension is added to 200 ml medium with 20 % DMSO and the cells are frozen as described above.

Example 3

DNA isolation and southern blot analysis for control and identification of picked colonies:

To characterize the clones, picked in example 2, DNA is isolated from the cells and examined. Therefore 500 μ l medium are added into any well of a picked colony which should still contain 60 μ l cell suspension (see example 2). The cells are cultured continuously 3-4 days until confluent for DNA isolation. 500 μ l lysis buffer (12 ml 1 M Tris-HCl (pH 8.3); 1.2 ml 0.5 M EDTA; 2.4 ml 10 % SDS; 4.8 ml 5 M NaCl; 1.2 ml 10 mg/ml proteinase K; 98.4 ml H₂O) is added, and it is incubated over night at 55°C. DNA is precipitated by adding 1 vol. 2-propanol and at least 15 min shaking at RT, and transferred with an Eppendorf tip into a 1.5 ml tube with 1 ml 70% EtOH. The tube is centrifuged for 10 min at RT to spin down the DNA. EtOH is removed and pellets are air dried for least one hour. DNA is dissolved afterward in 100 μ l TE for over night at 55°C.

Southern blot analysis:

1/3 of the isolated DNA was used for one digestion. The digestion was carried out for over night at 37°C. Loading buffer was added, and DNAs are separated in an agarose gel for least 6 hours. The gels were incubated in 0.2 N HCl for 15 min at room temperature; after 15 min HCl solution was
5 replaced by 0.4 N NaOH and the gel was incubated therein for 15 min at RT. The DNA was transferred onto nylon membranes (Amersham) over night using 0.4 N NaOH as transfer buffer using a vacuum blot machine (Stratagene). The membranes were neutralized in 2x SSC for 1 min, and air dried for least one hour. After UV-Crosslinking the DNA onto the membrane
10 hybridisation with DNA probes (probes are shown in figure 3) was carried out under standard conditions (QuickHyb from Clontech, 65°C, wash twice with 2x SSC, 0.1 % SDS at 65°C).

Production of transgenic animals with mutant parkin allele:

15
10-15 recombinant ES cells are injected into blastocysts. The blastocysts are implanted in pseudopregnant mice. The chimeric spring offs are crossed with wild type mice to obtain heterocygotic recombinant F1 mice. These mice are analysed by southern blot analysis as described above. Transgenic
20 mice are crossed with each other to obtain mice with both alleles modified (homozygote animals).

Descendants of the transgenic animals may be used for breeding with mice strains representing the same or any other genotype, preferred mice
25 strains showing neurological abnormalities, more preferred with strains showing neurodegenerative abnormalities. These other mouse strains may be selected from wild type mice, mice containing knock-ins or knock-outs, mice containing mutants of genes or mice which overexpress any gene product. The most preferred partners for breeding are mice which represent
30 a model for Alzheimer's disease, Huntigton' disease, amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease, Pick's disease or Prion disease.

Use of Transgenic Mice:

The animal can be used to test potential therapeutic agents. The test
5 group of mice is treated with the test compound administered in an
appropriate fashion for a set period. At the conclusion of the test
period, the animals are assessed behaviourally, biochemically, and
histologically for any possible effects of the test compound. The exact
10 protocol depends on the anticipated mechanism of action of the test
compound. Compounds that may have utility in treating Parkinson's disease
can be identified using this approach.

Such analysis can be carried out in the animal ,in primary tissue cultures
of the expressing cells or in immortalised cells derived from those
15 animals.

Mice expressing the truncated parkin2 protein gene or variants of the
described one can be used for testing the development of Parkinson's
disease during ageing of the animals. Beside the enhanced progression of
20 cell death in substantia nigra area, increased sensitivity to selective
neurotoxins like MPTP or 6-hydroxydopamine and enhanced response to
dopaminergic precursors like L-dopa may be examined.

Claims

1. A polynucleotide sequence encoding a mouse parkin2 protein, containing naturally occurring or artificially introduced mutations or deletions,
5 which cause Parkinson's disease in a human if they occur in the according human sequence.
2. The sequence of claim 1, wherein the sequence is genomic DNA, coding for a full-length parkin gene or fragments thereof, cDNA of a full
10 length parkin gene or fragments thereof, or RNA of a full length parkin gene or fragments thereof.
3. The sequence of claim 1 or 2, wherein the sequence is selected from the group, consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7 SEQ ID NO:8,
15 SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20 or naturally occurring or artificially introduced mutants or fragments thereof.
- 20 4. A vector, containing any sequence according to any of claims 1 to 3.
5. A prokaryotic or eukaryotic cell, containing a vector according to claim 4.
- 25 6. The cell of claim 5, characterised in that the cell is selected from bacterial or yeast cells, insect cells or mammalian cells as primary cells or immortalised cell lines.
7. A parkin mouse protein with an amino acid sequence of SEQ ID NO:5, SEQ
30 ID NO:6 SEQ, ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 or

naturally occurring or artificially introduced mutants with a homologous protein sequence or fragments thereof.

8. A transgenic non-human animal, whose one or both alleles of a gene
5 encoding a parkin gene are mutated or truncated in a way, that a protein with modified, preferred less activity or no active protein is expressed.
9. The transgenic animal of claim 8, wherein the parkin gene has any
10 mutation or deletion which are known to cause Parkinson's disease in a human if they occur in the according human sequence.
10. The transgenic non-human animal of claim 8 or 9, carrying a mutation
or deletion in one or both alleles of a gene encoding a parkin protein,
15 such that expression of said parkin gene produces a mutated or truncated protein or no protein, which causes said animal to display any physiological, biochemical or molecular biological features of a neurodegenerative disease.
- 20 11. The transgenic non-human animal of claim 10, carrying a deletion in one or both alleles of any of the exons of the gene encoding the parkin protein.
12. The transgenic non-human animal of any of claims 8 to 11, carrying a
25 DNA sequence according to any of the sequences SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7 SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20.
- 30 13. A mammalian cell-line transformed or transfected with any sequence according to any of claims 1 to 3 or a vector according to claim 4 or

cell lines or primary cultures derived from the transgenic animal of any of claims 8 to 12.

14. A method of producing a transgenic animal according to any of claims
5 8 to 12 or a cell line according to claim 13.

15. Use of the transgenic non-human animal according to any of claims 8
to 12 or a cell line according to claim 13 as a model for
neurodegenerative diseases.

10

16. A method for analyzing the symptoms of neurodegenerative diseases,
either outside of a living body using any of the polynucleotide
sequences of any of claims 1 to 4, any of the protein sequences of
claim 7, or using any model according to claim 15.

15

17. A method for testing the efficacy of a treatment for a
neurodegenerative disease associated with a less active or non-active
parkin protein, comprising subjecting any model of claim 15 to a
putative treatment and determining the efficacy of said treatment.

20

18. The method according to claim 16 or 17, wherein said
neurodegenerative disease is selected from the group consisting of
Parkinson's disease, Alzheimer's disease, Huntington's disease,
amyotrophic lateral sclerosis, Multisystem atrophy, Wilson's disease,
25 Pick's disease, Prion disease, or second causes inducing Parkinson's
syndromes like toxins, drugs, brain tumors, head trauma, stroke,
vascular irregularities, or metabolic irregularities.

19. The method of any of claims 17 to 19, wherein said treatment
30 comprises administering an active substance to the model.

20. Use of any model according to claim 15 for testing whether an active substance is useful for treating a condition associated with non-active parkin protein comprising administering said active substance to the transgenic animal of any of claims 8 to 12 or a cell-line of claim 13, and determining a level of the active substance, which causes an effect in treating the disease.
21. Use of the animal according to any of claims 8 to 12 as a model for examination of behaviour during the development of a neurodegenerative disease, or any model according to claim 15 for examination of pathobiochemical, immunobiological, neurological as well as histochemical effects of neurodegenerative diseases, physiological and molecular biological correlation of the disease, for studies of drug effects and for determination of effective drug doses and toxicity.
22. Descendant of the transgenic animal according to any of claims 8 to 12, obtained by breeding with the same or any other genotype.

hpARK2	1	MIVFVRFNSS	10	HGFPVEVDSD	20	TSIFQLKEVV	30	AKRQGV PADQ	40	LRVIFAGKEL	50
mpARK2	1										
hpARK2	51	RNDWTVQNCD	60	LDQQSIVHIV	70	QRPWRKGOEM	80	NATGGDDPRN	90	AAGGCEREPO	100
mpARK2	51	P.HL		E.		R.RSH.T		.S...E.QS		TSE.SIW.SR	100
hpARK2	101	SLTRVDLSSS	110	VLPGDSVGLA	120	VILHTDSRKD	130	SPPAGSPAGR	140	SIYNSFYVYC	150
mpARK2	101			T.V		...D...KR.		.EA.RG.V-K		PT....FI..	150
hpARK2	151	KGPCQORVQPG	160	KLRVQCSTCR	170	QATLTLTQGP	180	SCWDDVLIPN	190	RMSGECQSPH	200
mpARK2	151	...HK...		...G...K		...A...	D	200
hpARK2	201	CPGTSAEFFF	210	KCGAHP TSDK	220	ETPVALHLIA	230	TNSRNITCIT	240	CTDVRSPLV	250
mpARK2	201	...R...		...		D.S...N...T		S.R.S.P...A		...	250
hpARK2	251	FQCNSRHHVIC	260	LDCFHLYCVT	270	RLNDRQFVHD	280	PQLGYSLPCV	290	AGCPNSLIKE	300
mpARK2	251	...H...			A...		...	300
hpARK2	301	LHHFRILGEE	310	QYNRYQQYGA	320	EECVLQMGGV	330	LCPRPGCGAG	340	LLPEPDQRKV	350
mpARK2	301	...		T.	QG...	350
hpARK2	351	TCEGGNGLGC	360	GFAFCRECKE	370	AYHEGEC SAV	380	FEASGTTTQA	390	YRVDERAAEQ	400
mpARK2	351	...		V...D...		...D.DSL		L.P...A.S...		...K...	400
hpARK2	401	ARWEAASKET	410	IKKTTKPCPR	420	CHVPVEKNGG	430	CMHMKCPQPQ	440	CRLEWCWNCG	450
mpARK2	401	...E...		...		N.I		...		K	450
hpARK2	451	CEWNRVCMGD	460	HWFDV*	470		480		490		500
mpARK2	451	...A		*		500

Fig.1

2a/3

hPARK2	1	TCCGG	10	20	30	40	50	50
mPARK2	1	CT.A.CGAGG	60	70	80	90	100	50
hPARK2	51	CGCTGGTGGG	110	120	130	140	150	100
mPARK2	51	110	120	130	140	150	100
hPARK2	101	GGCCCGCAGC	160	170	180	190	200	150 Exon1/2
mPARK2	101	.A.....	160	170	180	190	200	150
hPARK2	151	AACTCCAGCC	210	220	230	240	250	200
mPARK2	151	210	220	230	240	250	200
hPARK2	201	CCAGCTCAAG	260	270	280	290	300	250
mPARK2	201	G.....	260	270	280	290	300	250
hPARK2	251	TGCGTGTGAT	310	320	330	340	350	300 Exon2/3
mPARK2	251	310	320	330	340	350	300
hPARK2	301	AATTGTGACC	360	370	380	390	400	350
mPARK2	301	.C.....	360	370	380	390	400	350
hPARK2	351	GAGAAAGGT	410	420	430	440	450	400
mPARK2	351	..G.G.A..	410	420	430	440	450	400
hPARK2	401	CGCGGGGAGG	460	470	480	490	500	450
mPARK2	401	.CT.A.AG..	460	470	480	490	500	450
hPARK2	451	AGCAGCTCAG	510	520	530	540	550	500
mPARK2	451	510	520	530	540	550	500
hPARK2	501	CACTGACAGC	560	570	580	590	600	550 Exon3/4
mPARK2	501	..A.....	560	570	580	590	600	550
hPARK2	551	CAATCTACAA	610	620	630	640	650	600
mPARK2	551	.C.C.....	610	620	630	640	650	600
hPARK2	601	CAGCCGGGAA	660	670	680	690	700	650
mPARK2	601	660	670	680	690	700	650
hPARK2	651	CACCTTGACC	710	720	730	740	750	700 Exon4/5
mPARK2	651	710	720	730	740	750	700
hPARK2	701	GGATGAGTGG	760	770	780	790	800	750 Exon5/6
mPARK2	701	760	770	780	790	800	750
hPARK2	751	TTTTTCTTTA	810	820	830	840	850	800
mPARK2	751	810	820	830	840	850	800

Fig 2

2b/3

hPARK2	801	810	820	830	840	850
mPARK2	801	AGCTTTGCAC	CTGATCGCAA	CAAATAGTCG	GAACATCACT	TGCATTACGT
	A..A.C.	GC..C..G..	C.G....C..AG...
hPARK2	851	GCACAGACGT	CAGGAGCCCC	GTCCTGGTTT	TCCAGTGCAA	CTCCCGCCAC
mPARK2	851T..T..C..T..	..CA...T..
		910	920	930	940	950
hPARK2	901	GTGATTGTCT	TAGACTGTTT	CCACTTATAC	TGTGTGACAA	GACTCAATGA
mPARK2	901C..T.G..T.G..T.C..C..
		960	970	980	990	1000
hPARK2	951	TCGGCAGTTT	GTTACAGACC	CTCAACTTGG	CTACTCCCTG	CCTTGTGTGG
mPARK2	951T..TGT..T..A..
		1010	1020	1030	1040	1050
hPARK2	1001	CTGGCTGTCC	CAACTCCTTG	ATTAAAGAGC	TCCATCACTT	CAGGATTCTG
mPARK2	1001T..C..T..C..TC..T
		1060	1070	1080	1090	1100
hPARK2	1051	GGAGAAGAGC	AGTACAACCG	GTACCAGCAG	TATGGTGCAG	AGGAGTGTGT
mPARK2	1051T..CTA..T..G..C..A..C..
		1110	1120	1130	1140	1150
hPARK2	1101	CCTGCAGATG	GGGGCGTGT	TATGCCCCCG	CCCTGGCTGT	GGAGCGGGGC
mPARK2	1101	G.....A..A..T..CG..T..A..T..A..
		1160	1170	1180	1190	1200
hPARK2	1151	TGCTGCCGGA	GCCTGACCAG	AGGAAAGTCA	CCTGCGAAGG	GGGCAATGGC
mPARK2	1151A..T..A..G..GT..C..C..
		1210	1220	1230	1240	1250
hPARK2	1201	CTGGGCTGTG	GGTTTGCTTT	CTGCCGGGAA	TGTAAGAAG	CGTACCATGA
mPARK2	1201C..TT..C..G..A..
		1260	1270	1280	1290	1300
hPARK2	1251	AGGGAGTGC	AGTGCCGTAT	TTGAAGCCTC	AGGAACAAC	ACTCAGGCCT
mPARK2	1251T..AC..GCC..C..G..C..T..
		1310	1320	1330	1340	1350
hPARK2	1301	ACAGAGTCGA	TGAAAGAGCC	GCCGAGCAGG	CTCGTTGGGA	AGCAGCCTCC
mPARK2	1301G..G..CA..T..C..G..AG..
		1360	1370	1380	1390	1400
hPARK2	1351	AAAGAAACCA	TCAAGAAAC	CACCAAGCCC	TGTCCCCGCT	GCCATGTACC
mPARK2	1351G..G..T..T..A..C..G..
		1410	1420	1430	1440	1450
hPARK2	1401	AGTGGAAAAA	AATGGAGGCT	GCATGCACAT	GAAGTGTCCG	CAGCCCCCAGT
mPARK2	1401A..T..C..T..T..T..
		1460	1470	1480	1490	1500
hPARK2	1451	GCAGGCTCGA	GTGGTGTCTGG	AACTGTGGCT	GCGAGTGGAA	CCGCGTCTGC
mPARK2	1451A..G..T..T..T..A..C..
		1510	1520	1530	1540	1550
hPARK2	1501	ATGGGGGACC	ACTGTTTCGA	CGTGTAGCCA	GGGCGGCCGG	GCGCCCCATC
mPARK2	1501A..T..T..AG..A..AT..T..AC	TT..G..TG
		1560	1570	1580	1590	1600
hPARK2	1551	GC-CACATCC	TGGGGGAGCA	TACCCAG--T	GTCTACCTTC	ATTT.....
mPARK2	1551	A.G.....A..	CAA..GAA..	CT..G.AGA..	TC.....	C..A.....




Fig 3

SEQUENZPROTOKOLL

<110> Firma Biofrontera GmbH

<120> Transgenic animal model for neurodegenerative diseases

<130> 5807EPAlleSequenzen

<140>

<141>

<160> 34

<170> PatentIn Ver. 2.1

<210> 1

<211> 3255

<212> DNA

<213> mouse

<400> 1

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120
cgggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggteg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt ttgtccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggt cattctggac acagacagta agagggatc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaaacaagc aaccctcacc ttggccagg 660
gcccattctg ctgggacgat gtcttaattc caaacccgat gagtgggtgag tgccagtctc 720
cagactgccc tggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttcca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgctca acttggttac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcacttcagg atccttggag aagagcagta cactaggtag cagcagtatg 1080
gggcccagga atgcgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
gctgcgggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgtc 1380
ctcgctgcaa cgtgccaat gaaaaaacg gaggatgtat gcacatgaag tgcctcagc 1440
cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1500
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccttgagcg acaacctcaa 1560
gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620

```

```

cataaatgcg cacacacaaa cacaggetgc agattacaga agcagcccct agatcctttc 1680
tagggcaccc acagaaaacc acagcacccg ctggccccag ggggaggagg cacttttcagc 1740
ctctggctca ctggaatgtc agagcttaga tgagggtgca cctttgggtt ggattctgta 1800
gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920
atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat ccccccaaat 1980
cctatcttta caaatggtgc tgatgagatt acaaccctc tgtgtactaa tcagcttatt 2040
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaate gcaggaggga 2100
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aacttttagaa agaatgatac 2160
tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tctactgca 2220
gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcggtt 2280
ttaagagaca atcccatgat gctgcgcaa tgctaacaac agggtaaga aacacaatgt 2340
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc tccaccaca 2400
agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460
ccaccagtg gtccacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520
atgcacaca ctcaagtgtt aatctttcaa ggttttcttt tctttttctt gttttttatt 2580
tgttttgctt ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tcccagtggt cctagactcc acccagccag cccccaaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tatttttttt 2820
ccatcattgt gcttgccctt gcctccctcc acaccctgtg gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggaact ccctgaagct ctgtggctct 2940
ccagtatggc cctttttctt tcttaacaga tgcataatgt ttcttcagaa tacaatagtg 3000
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060
attgtgtgag tgtgaatagt gggataaaaag tggatgtcag aagagtggaa atcaaacctc 3120
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaaaa

```

3255

<210> 2

<211> 1459

<212> DNA

<213> mouse

<400> 2

```

ctcacgggga ggaggccttg gatgactaaa cctgacagaa acgctggtgg gaggctcggg 60
cgggcgccag tgcccgctga ggtccttctc gaccgcagc caccaccgc cgggtgacca 120
tgatagtgtt tgtcagggtc aactccagct atggcttccc agtggaggtc gattctgaca 180
ccagcatctt gcagctcaag gaagtgttg ctaagcgaca gggggttcca gctgaccagc 240
tgcggtgtgat ttttgccggg aaggagcttc cgaatcacct gacggttcaa aactgtgacc 300
tggaacaaca gagtattgta cacatagtac agagaccacg gaggagaagt catgaaaca 360
atgcacatctg aggggacgaa cccagagca cctcagaggg ctccatatgg gagtccagga 420
gcttgacacg agtggacctg agcagccata ccctgcgggt ggactctgtg gggctggcgg 480
tcattctgga cacagacagt aagagggtt cagaagcagc cagagggtcca gcagttaaac 540
ccacctacaa cagctttttc atctactgca aaggcccttg ccacaaggte cagcctggaa 600
agctccgagt tcagtgtggc acctgcaaac aagcaaccct cacttggtcc cagggcccat 660
cttgctggga cgatgtctta attccaaacc ggatgagtgg tgagtgcag tctccagact 720
gcctggaac cagagctgaa tttttcttta aatgtggagc acaccaacc tcagacaagg 780

```

```

acacgtcggg agctttgaac ctgatacca gcaacaggcg cagcatccct tgcatagcgt 840
gcacagatgt cagtcattct cctctgtcat ctgggtgcctc cgtgtggact cggcctcctc 900
tccactgaac cttgttcttt aggactgtgc aataggctcg caccctctac tgagaacaag 960
gcagcttctg gtctcttggg ttctctgctt ccaacggcag cattgactgt acacccttca 1020
gtcctaccaaa cccattacc tgggtgattt ctttaccgct tagcttctcc aagatgccta 1080
tttccacaca cagtttcttg tcttcccat ccccccata gtttatgcgc atgagtaagc 1140
accgcacctc atgagtttgt gcttctgata caagacttcc tgggatcccc gcttgagccc 1200
tagaatcccc tggaactggg ttcagtcacc tatcttcaat agcctctttt aaaagtgggt 1260
tcttgggctg gtgagatggc tcagtgggta agagcacccg actgctcttc cgaagtccag 1320
agttcaaaat cccagcaacc acatgggtggc tcacaacccat ccgtaacaag atctgactcc 1380
ctcttctggg gtgtctgaag acagctacag tgtacttaca taaaataata aataaatctt 1440
aaaaaaaaaa aaaaaaaaaa

```

1459

<210> 3

<211> 857

<212> DNA

<213> mouse

<400> 3

```

ctcagatgac taaacctgac agaaacgctg gtgggagggt cgggcgggcg ccagtgcctg 60
cgtaggctcct tctcgaccgg cagccaccac ccgcccgggtg accatgatag tgtttgtcag 120
gttcaactcc agctatggct tcccagtggg ggctcgattct gacaccagca tcttgcagct 180
caagggaagtg gttgctaagc gacagggggg tccagctgac cagctgcgtg tgatttttgc 240
cgggaaggag cttccgaatc acctgacggg tcaaaactgt gacctggaac aacagagtat 300
tgtacacata gtacagagac cacggaggag aagtcattgaa acaaattgcat ctggagggga 360
cgaaccccgag agcacctcag agggctccat atgggagctc aggagcttga cagagtgga 420
cctgagcagc cataccctgc cgggtggactc tgtggggctg gcggctattc tggacacaga 480
cagtaagagg gattcagaag cagccagagg tccagcagtt aaaccacctt acaacagctt 540
tttcatctac tgcaaaggcc cctgccacaa ggtccagcct ggaaagctcc gagttcagtg 600
tggcacctgc aaacaagcaa cctcacctt ggcccagggc ccatcttctg gggacgatgt 660
cttaattcca aaccggatga gtgggtgagt ccagttctca gactgccctg gaaccagagc 720
tgaatttttc tttaaatgtg gagcacaccc aacctcagac aaggacacgt cggtagcttt 780
gaacctgatc accagcaaca ggcgcagcat ccttgcata gcgtgcacag atgtcaggtt 840
tatgcgcagt agttagc

```

857

<210> 4

<211> 464

<212> PRT

<213> mouse

<400> 4

```

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1                      5                      10                      15

```

```

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
      20                      25                      30

```

```

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys

```


35	40	45
Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln		
50	55	60
Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr		
65	70	75 80
Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile		
85	90	95
Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu		
100	105	110
Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys		
115	120	125
Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser		
130	135	140
Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys		
145	150	155 160
Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala		
165	170	175
Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser		
180	185	190
Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe		
195	200	205
Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala		
210	215	220
Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys		
225	230	235 240
Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His		
245	250	255
Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn		
260	265	270
Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys		
275	280	285
Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg		

290	295	300
Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu		
305	310	315 320
Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys		
325	330	335
Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu		
340	345	350
Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys		
355	360	365
Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly		
370	375	380
Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala		
385	390	395 400
Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro		
405	410	415
Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His		
420	425	430
Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys		
435	440	445
Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val		
450	455	460

<210> 5
 <211> 262
 <212> PRT
 <213> mouse

<400> 5
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Ala Val Lys Pro Thr Tyr Asn
 130 135 140
 Ser Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly
 145 150 155 160
 Lys Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu
 165 170 175
 Ala Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met
 180 185 190
 Ser Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe
 195 200 205
 Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val
 210 215 220
 Ala Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala
 225 230 235 240
 Cys Thr Asp Val Ser His Leu Pro Leu Ser Ser Gly Ala Ser Val Trp
 245 250 255
 Thr Arg Pro His Leu His
 260

<210> 6

<211> 250

<212> PRT

<213> mouse

<400> 6

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Ala Val Lys Pro Thr Tyr Asn
 130 135 140

Ser Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly
 145 150 155 160

Lys Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu
 165 170 175

Ala Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met
 180 185 190

Ser Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe
 195 200 205

Phe Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val
 210 215 220

Ala Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala
 225 230 235 240

Cys Thr Asp Val Arg Phe Met Arg Met Ser
245 250

<210> 7

<211> 3014

<212> DNA

<213> mouse

<400> 7

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accacccgcc 120
cggtgaccat gatagtgttt gtcagggtca actccagcta tggcttccca gtggaggteg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaat 300
taaaccacc tacaacagct ttttcatcta ctgcaaagge ccctgccaca aggtccagcc 360
tggaagctc cgagttcagt gtggcacctg caaacaagca accctcacct tggcccagg 420
cccatcttgc tgggacgatg tcttaattcc aaaccggatg agtgggtgagt gccagtctcc 480
agactgccct ggaaccagag ctgaattttt ctttaaagt gtggcacacc caacctcaga 540
caaggacacg tcggtagctt tgaacctgat caccagcaac aggcgcagca tcccttgcac 600
agcgtgcaca gatgtcagga gccctgtcct ggtcttccag tgtaaccacc gtcacgtgat 660
ctgtttggac tgtttccact tgtattgtgt cacaagactc aacgatcggc agtttgtcca 720
cgatgctcaa cttgggtact ccctgccgtg tgtagctggc tgtcccaact ccctgattaa 780
agagctccat cacttcagga tccctggaga agagcagtac actaggtagc agcagtatgg 840
ggccgaggaa tgcgtgctgc aaatgggagg tgtgctgtgc ccccgtcctg gctgtggagc 900
tggaactgcta cctgaacagg gccagaggaa agtcacctgc gaagggggca acggcctggg 960
ctgcgggttt gttttctgcc gggactgtaa ggaagcatac catgaagggg attgcgactc 1020
actgctcgaa ccctcaggag ccacttctca ggcctacagg gtggacaaaa gagccgctga 1080
gcaagctcgc tgggaggagg cctccaagga aaccatcaag aagaccacca agccttgtcc 1140
tcgctgcaac gtgccaattg aaaaaacgg aggatgtatg cacatgaagt gtcctcagcc 1200
ccagtgcagg ctggagtggg gctggaactg tggctgtgag tggaaaccag cctgcatggg 1260
agatcactgg tttgacgtgt agagagagat gtcacttggc cctggacgca caacctcaag 1320
ggaaactcgc aagattccta ccttccttag ccatttcttc ttctcgatgc atataagcac 1380
ataaatgcgc acacacaaac acaggctgca gattacagaa gcagccccta gatcctttct 1440
agggcaccca cagaaaacca cagcaccgcg tggccccagg gggaggaggc actttcagcc 1500
tctggctcac tcgaatgtca gagcttagat gagggtgcac ctttgggttg gattctgtag 1560
aagccatgag tgagggtgga agtgttttcc aggggtgttg ccacgcctg ggtaagtaac 1620
acctctgagg attctcagaa gcacacttga gatctgagga acgctgctct catgtagtaa 1680
tcattctatc ccaaagggcc ccctgcagta gtcaaaacta tttgtttatc ccccaaatc 1740
ctatctttac aaatggtgct gatgagatta caaccctct gtgtactaat cagcttatca 1800
accaagttag aacctaggaa agctaattgg atggcagact gcttaaatcg caggaggagc 1860
tcagaagcca aacctacttc cgttcgtttc attatctgca actttagaaa gaaatgatct 1920
ttttttcccc ctgaaaagat aacaaagtct gcaatttggg ttggagtatt cctactgcag 1980
cctggaagtt tagcttcact gtgaatttaa cagagaaagt gcctataaag ggggcgtttt 2040
taagagacaa tcccatgatg ctgcgccaat gctaacaaca gggtaagaa acacaatgtt 2100
tatagaagga gcacccctcg accatctgaa tgagagtatg cctgaccctc tccaccacaa 2160
gtggggacac ctctgcatat ctgtccctc ctctgctgtt aagccccagg gagccccatc 2220

```

```

caccagtggtg tccacagac agggcaatac acacacacca agatagcctt cagatcaaca 2280
tgcacacac tcaagtgtta atctttcaag gttttctttt ctttttcttg ttttttattt 2340
gttttgcttt tgcttttttt tttttttttt ttggtggtgg tggggctacc aaacttgagg 2400
cctagagcta aaaatcatat agaaatgatg ttatcttggt gtgtgaggaa aggccagctg 2460
gcctaagttc acacttttgt cccagtggcc ctaga'ctcca cccagccagc tcccaaaatg 2520
aaaagaccac ctgtcaagca gcagtcagga gtctgatgtc acccatcact attttttttc 2580
catcattgtg cttgcctctg cctccttcca caccggtgtg acgtaatcgc attgggaagc 2640
caggacaatg tttgctgttc tgctttgggt aaagggactc cctgaagctc tgtggctctc 2700
cagtatggte ccttttctct cctaacagat gcatatgttt tcttcagaat acaatagtga 2760
ttcttaaaat aacccaaaag acaggcatcc acagtgtgtg agcatgaatc acagcctgca 2820
ttgtgtgagt gtgaatagtg ggataaaagt ggatgtcaga agagtggaaa tcaaacctct 2880
gcaaagcaat ctttctcttt ctgtgaagtg tattaagaaa tacctgaagt ctgtgtgtgt 2940
ggtggtaccc agactgtcaa tcaataaaga cccagactgt caatgaaaaa aaaaaaaaaa 3000
aaaaaaaaaa aaaa                                     3014

```

<210> 8

<211> 2895

<212> DNA

<213> mouse

<400> 8

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgctag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggttccca gtggaggteg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaag 300
gcccatcttg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 360
cagactgccc tgggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 420
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 480
tagcgtgcac agatgtcagg agcctgtcc tgggtcttcca gtgtaaccac cgtcacgtga 540
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 600
acgatgctca acttggttac tcctgccgt gtgtagctgg ctgtcccaac tccttgatta 660
aagagctcca tcacttcagg atccttgag aagagcagta cactaggtag cagcagtatg 720
gggcccagga atgctgtctg caaatgggag gtgtgctgtg ccccgctct ggctgtggag 780
ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 840
gctgcgggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 900
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 960
agcaagctcg ctgggaggag gctccaagg aaaccatcaa gaagaccacc aagccttgct 1020
ctcgtgcaa cgtgccaat gaaaaaacg gaggatgtat gcacatgaag tgcctcagc 1080
cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1140
gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggagc acaacctcaa 1200
gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1260
cataaatgag cacacacaaa cacaggctgc agattacaga agcagccct agatcctttc 1320
tagggcacc acagaaaacc acagcaccg ctggccccag ggggaggagg cactttcagc 1380
ctctggctca ctgaatgtc agagcttaga tgagggtgca cctttgggtt ggattctgta 1440
gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1500
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1560
atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat ccccccaat 1620

```

```

cctatcttta caaatgggtgc tgatgagatt acaacccttc tgtgtactaa tcagcttate 1680
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaatc gcaggaggga 1740
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aacttttagaa agaaatgate 1800
tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tcctactgca 1860
gcctggaagt ttagcttcac tgtgaattta acagagaaaag tgccataaaa gggggcggtt 1920
ttaagagaca atcccatgat gctgcgcaa tgctaacaac agggccaaga aacacaatgt 1980
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2040
agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2100
ccaccagtg gtcctacaga cagggaata cacacacacc aagatagcct tcagatcaac 2160
atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2220
tgttttgctt ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2280
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2340
ggcctaagtt cacacttttg tcccagtggc cctagactcc accagccag ctcccaaat 2400
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tttttttttt 2460
ccatcattgt gcttgccctc gcctccttc acaccgtgt gacgtaatcg cattgggaag 2520
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2580
ccagtatggt cccttttctt tcctaacaga tgcataatgt ttcttcagaa tacaatagtg 2640
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 2700
attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 2760
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 2820
tggtgttacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 2880
aaaaaaaaa aaaaaa

```

2895

<210> 9

<211> 2558

<212> DNA

<213> mouse

<400> 9

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtcccttctcg acccgccagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggagggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaac 300
tggctgtccc aactccctga ttaaagagct ccatcacttc aggatccttg gagaagagca 360
gtacactagg taccagcagt atggggccga ggaatgcgtg ctgcaaatgg gaggtgtgct 420
gtgcccccggt cctggctgtg gagctggact gctacctgaa cagggccaga ggaaagtcac 480
ctgcgaaggg ggcaacggcc tgggctgcgg gtttgttttc tgccgggact gtaaggaagc 540
ataccatgaa ggggattgct actcactgct cgaacctca ggagccactt ctcaggccta 600
cagggtggac aaaagagccg ctgagcaagc tcgctgggag gaggcctcca aggaaccat 660
caagaagacc accaagcctt gtcctcgctg caacgtgcc aattgaaaaa acggaggatg 720
tatgcacatg aagtgtcctc agccccagt caagctggag tgggtgctgga actgtggtg 780
tgagtggaac cgagcctgca tgggagatca ctggtttgac gtgtagagag agatgtcact 840
tggccctgga cgcacaacct caagggaaac tccgaagatt cctaccttcc ttagccattt 900
cttcttctcg atgcatataa gcacataaat gcgcacacac aaacacaggc tgcagattac 960
agaagcagcc cctagatcct ttctagggca cccacagaaa accacagcac ccgctggccc 1020
cagggggagg aggcacttcc agcctctggc tcaactgaat gtcagagctt agatgagggt 1080
gcacctttgg tttggattct gtagaagcca tgagtgaggt gggaagtgtt ttccagggtt 1140

```

```

gttgccacgc cctgggtaag taacacctct gaggattctc agaagcacac ttgagatctg 1200
aggaacgctg ctctcatgta gtaatcatct attcccaaag ggccccctgc agtagtcaaa 1260
actatttggt tatcccccca aatcctatct ttacaaatgg tgctgatgag attacaaccc 1320
ctctgtgtac taatcagctt atcaaccaag tgagaacctt ggaaagctaa ttggatggca 1380
gactgcttaa atcgcaggga ggactcagaa gccaaacctt cttccgttcg tttcattatc 1440
tgcaacttta gaaagaaatg atcttttttt cccctgaaa agataacaaa gtctgcaatt 1500
tggtttggag tattcctact gcagcctgga agtttagctt cactgtgaat ttaacagaga 1560
aagtgcctat aaagggggcg tttttaagag acaatcccat gatgctgcgc caatgctaac 1620
aacagggcca agaaacacaa tgtttataga aggagcatcc ctgcaccatc tgaatgagag 1680
tatgcctgac ccctccacc acaagtgggg acacctctgc atatctgctc cctcctctgc 1740
tggttaagccc caggagccc catccacca gtggtcctac agacagggca atacacacac 1800
accaagatag ccttcagatc aacatgcac acactcaagt gttaatcttt caaggttttc 1860
ttttcttttt cctgtttttt atttgttttg cttttgcttt tttttttttt ttttttggtg 1920
gtggtggggc taccaaactt gaggcctaga gctaaaaatc atatagaaat gatgttatct 1980
tgtggtgtga ggaaaggcca gctggcctaa gttcacactt ttgtcccagt ggccctagac 2040
tccaccacgc cagctcccaa aatgaaaaga ccacctgtca agcagcagtc aggagtctga 2100
tgtcaccat cactattttt tttccatcat tgtgcttgcc tctgcctcct tccacaccgc 2160
tgtgacgtaa tcgcattggg aagccaggac aatgtttgct gttctgcttt gggtaaaggg 2220
actccctgaa gctctgtggc tctccagtat ggtccctttt ccttcctaac agatgcatat 2280
gttttcttca gaatacaata gtgattctta aaataaccca aaagacaggc atccacagtg 2340
tgtgagcatg aatcacagcc tgcattgtgt gagtgtgaat agtgggataa aagtggatgt 2400
cagaagagtg gaaatcaaac ctctgcaag caatctttct cttctgtga agtgtattaa 2460
gaaatacctg aagtctgtgt gtgtggtggt acccagactg tcaatcaata aagaccacga 2520
ctgtcaatga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

```

2558

<210> 10

<211> 3136

<212> DNA

<213> mouse

<400> 10

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgtggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg accgcagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt ttgcccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccagc aggagaagtc 360
atgaaacaaa tgcatctgga ggggacgaac ccagagcac ctcagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggetggcggt cattctggac acagacagta agagggatc agaagcagcc agaggtccag 540
ggcccatctt gctgggacga tgtcttaatt ccaaaccgga tgagtgggtg gtgccagtct 600
ccagactgcc ctggaaccag agctgaattt ttctttaaat gtggagcaca cccaacctca 660
gacaaggaca cgtcggtagc tttgaacctg atcaccagca acaggcgag catcccttgc 720
atagcgtgca cagatgtcag gagccctgtc ctggtcttcc agtgtaacca ccgtcacgtg 780
atctgttttg actgtttcca cttgtattgt gtcacaagac tcaacgatcg gcagtttgtc 840
cacgatgtc aacttggtta ctccctgccg tgtgtagctg gctgtcccaa ctccctgatt 900
aaagagctcc atcacttcag gatccttggg gaagagcagt acactaggta ccagcagtat 960
ggggccgagg aatgcgtgct gcaaattggg ggtgtgctgt gccccgtcc tggtgtgga 1020

```



```

gctggactgc tacctgaaca gggccagagg aaagtcacct gcgaaggggg caacggcctg 1080
ggctgcgggg ttgttttctg cggggactgt aaggaagcat accatgaagg ggattgcgac 1140
tactgctcg aacctcagg agccacttct caggcctaca gggaggacaa aagagccgct 1200
gagcaagctc gctgggagga ggcctccaag gaaaccatca agaagaccac caagccttgt 1260
cctcgctgca acgtgccaat tgaaaaaac ggaggatgta tgcacatgaa gtgtcctcag 1320
ccccagtgca agctggagtgt gtgctggaac tgtggctgtg agtggaaacc agcctgcatg 1380
ggagatcact ggtttgacgt gtagagagag atgtcacttg gccctggacg cacaacctca 1440
agggaaactc cgaagattcc taccttcctt agccatttct tcttctcgat gcatataagc 1500
acataaatgc gcacacacaa acacaggctg cagattacag aagcagcccc tagatccttt 1560
ctagggcacc cacagaaaac cacagcaccg gctggcccca gggggaggag gcactttcag 1620
cctctggctc actcgaatgt cagagcttag atgagggtgc acctttgggt tggattctgt 1680
agaagccatg agtgagggtg gaagtgtttt ccagggttgt tgccacgccc tgggtaagta 1740
acacctctga ggattctcag aagcacactt gagatctgag gaacgctgct ctcatgtagt 1800
aatcatctat tcccaaaggg cccctgcag tagtcaaac tatttgttta tcccccaa 1860
tcctatcttt acaaatggtg ctgatgagat tacaaccctt ctgtgtacta atcagcttat 1920
caaccaagtg agaacctagg aaagctaatt ggatggcaga ctgcttaaat cgcaggagg 1980
actcagaagc caaacctact tccgttcgtt tcattatctg caactttaga aagaaatgat 2040
ctttttttcc cctgaaaag ataacaaagt ctgcaatttg gtttgagta ttctactgc 2100
agcctggaag tttagcttca ctgtgaattt aacagagaaa gtgcctataa agggggcggt 2160
tttaagagac aatcccatga tgctgcgcca atgctaacaa cagggtcaag aaacacaatg 2220
tttatagaag gagcatccct cgaccatctg aatgagagta tgcctgacct ctccaccac 2280
aagtggggac acctctgcat atctgtctcc tctctgtctg ttaagcccc gggagcccc 2340
tccacccagt ggtcctacag acagggaat acacacacac caagatagcc ttcagatcaa 2400
catgcatcac actcaagtgt taatctttca aggttttctt ttctttttcc tgttttttat 2460
ttgttttget tttgtttttt tttttttttt ttttggtggt ggtggggcta ccaaacttga 2520
ggcctagagc taaaaatcat atagaaatga tgttatcttg tgggtgtgagg aaaggccagc 2580
tggcctaagt tcacactttt gtcccagtgg ccctagactc caccagcca gctcccaaaa 2640
tgaaaagacc acctgtcaag cagcagtcag gagtctgatg tcacccatca ctattttttt 2700
tccatcattg tgcttgctc tgctctcttc cacaccctg tgacgtaate gcattgggaa 2760
gccaggacaa tgtttgctgt tctgcttttg gtaaaggac tccctgaagc tctgtggctc 2820
tccagtatgg tcccttttcc ttccaaacag atgcataatgt tttcttcaga atacaatagt 2880
gattcttaaa ataaccctaa agacaggcat ccacagtgtg tgagcatgaa tcacagcctc 2940
cattgtgtga gtgtgaatag tgggataaaa gtggatgtca gaagagtgga aatcaaacct 3000
ctgcaaagca atctttctct ttctgtgaag tgtattaaga aatacctgaa gtctgtgtgt 3060
gtggtgtgtac ccagactgtc aatcaataaa gaccagact gtcaatgaaa aaaaaaaaaa 3120
aaaaaaaaaa aaaaaa

```

3136

<210> 11
 <211> 3170
 <212> DNA
 <213> mouse

<400> 11
 ctacgcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
 aggcctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accaccgccc 120
 cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctc 180
 attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
 ctgaccagct gcgtgtgatt tttgcgggga aggagcttcc gaatcacctg acggttcaaa 300

actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
 atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
 agtccaggag cttgacacga gtggacctga gcagccatac cctgccgggtg gactctgtgg 480
 ggctggcggt cattctggac acagacagta agagggatc agaagcagcc agaggtccag 540
 ttaaaccac ctacaacagc tttttcatct actgcaaaagg cccctgccac aaggtccagc 600
 ctggaaagct ccgagttcag tgtggcacct gcaacaacag aacctcacc ttggcccaga 660
 atttttcttt aaatgtggag cacacccaac ctcagacaag gacacgtcgg tagctttgaa 720
 cctgatcacc agcaacaggc gcagcatccc ttgcatagcg tgcacagatg tcaggagccc 780
 tgtcctgggtc ttccagtgtg accaccgtca cgtgatctgt ttggactgtt tccacttgta 840
 ttgtgtcaca agactcaacg atcggcagtt tgtccacgat gctcaacttg gctactccct 900
 gccgtgtgta gctggctgtc ccaactccct gattaaagag ctccatcact tcaggatcct 960
 tggagaagag cagtacacta ggtaccagca gtatggggcc gaggaatgcg tgctgcaaat 1020
 gggagggtgt ctgtgcccc gtcctggctg tggagctgga ctgctacctg aacagggcca 1080
 gaggaagtc acctgcgaag ggggcaacgg cctgggctgc gggtttggtt tctgccggga 1140
 ctgtaaggaa gcataccatg aaggggattg cgactcactg ctcgaacctt caggagccac 1200
 ttctcaggcc tacagggtgg acaaaagagc cgctgagcaa gctcgtggg aggaggccct 1260
 caaggaaacc atcaagaaga ccaccaagcc ttgtcctcgc tgcaacgtgc caattgaaaa 1320
 aaacggagga tgtatgcaca tgaagtgtcc tcagccccag tgcaagctgg agtggtgtcg 1380
 gaactgtggc tgtgagtga accgagcctg catgggagat cactggtttg acgtgtagag 1440
 agagatgtca cttggccctg gacgcacaac ctcaaggga actccgaaga ttctacctt 1500
 ccttagccat ttcttcttct cgatgcatat aagcacataa atgcgcacac acaaacacag 1560
 gctgcagatt acagaagcag cccctagatc ctttctaggg caccacaga aaaccacagc 1620
 acccgctggc cccaggggga ggaggcactt tcagcctctg gctcactcga atgtcagagc 1680
 ttagatgagg gtgcacctt ggtttggatt ctgtagaagc catgagttag gtgggaagtg 1740
 ttttccaggg ttgttgccac gccctgggta agtaaacct ctgaggattc tcagaagcac 1800
 acttgagatc tgaggaacgc tgctctcatg tagtaatcat ctattcccaa agggccccct 1860
 gcagtagtca aaactatttg tttatcccc caaatcctat ctttacaat ggtgctgatg 1920
 agattacaac cctctgtgt actaatcagc ttatcaacca agtgagaacc taggaaagct 1980
 aattggatgg cagactgctt aaatcgcagg gaggactcag aagccaaacc tacttccgtt 2040
 cgtttcatta tctgcaactt tagaaagaaa tgatcttttt tttccctga aaagataaca 2100
 aagtctgcaa tttggtttg agtattccta ctgcagcctg gaagtttagc ttactgtga 2160
 atttaacaga gaaagtgcct ataaagggg cgtttttaag agacaatccc atgatgctgc 2220
 gccaatgcta acaacagggt caagaaacac aatgtttata gaaggagcat cctcgacca 2280
 tctgaatgag agtatgcctg accccttcca ccacaagtgg ggacacctct gcatactctgc 2340
 tccctcctct gctgttaagc cccagggagc cccatccacc cagtggctct acagacaggg 2400
 caatacacac acaccaagat agccttcaga tcaacatgca tcacactcaa gtgttaatct 2460
 ttcaaggttt tcttttcttt ttctgtttt ttattgtttt tgcttttgct ttttttttt 2520
 ttttttttgg tgggtggtgg gctaccaaac ttgaggccta gagctaaaaa tcatatagaa 2580
 atgatgttat cttgtggtgt gaggaaggc cagctggcct aagttcacac ttttgtccca 2640
 gtggccctag actccacca gccagctccc aaaatgaaaa gaccacctgt caagcagcag 2700
 tcaggagtct gatgtcacc atcactatct ttttccatc attgtgcttg cctctgcctc 2760
 cttccacacc cgtgtgacgt aatcgcattg ggaagccagg acaatgtttg ctgttctgct 2820
 ttgggtaaag ggactccctg aagctctgtg gctctccagt atggctccct ttccttcta 2880
 acagatgcat atgttttctt cagaatacaa tagtgattct taaaataacc caaaagacag 2940
 gcattccacag tgtgtgagca tgaatcacag cctgcattgt gtgagtgtga atagtgggat 3000
 aaaagtggat gtcagaagag tggaaatcaa acctctgcaa agcaatcttt ctctttctgt 3060
 gaagtgtatt aagaaatacc tgaagtctgt gtgtgtggtg gtaccagac tgtcaatcaa 3120
 taaagacca gactgtcaat gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3170

<210> 12
<211> 2918
<212> DNA
<213> mouse

<400> 12

```
ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggagggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
atgaaacaaa tgcattctga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggg cattctggac acagacagta agagggtatc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaacaagc aacctcacc ttggcccagc 660
tggctgtccc aactccctga ttaaagagct ccatcacttc aggatccttg gagaagagca 720
gtacactagg taccagcagt atggggccga ggaatgcgtg ctgcaaattg gaggtgtgct 780
gtgccccctg cctggctgtg gagctggact gctacctgaa caggggccaga ggaaagtcac 840
ctgcgaaggg ggcaacggcc tgggctgcgg gtttgttttc tgcggggact gtaaggaagc 900
ataccatgaa ggggatttgc actcactgct cgaacctca ggagccactt ctcaggccta 960
cagggtggac aaaagagccg ctgagcaagc tcgctgggag gaggcctcca aggaaacct 1020
caagaagacc accaagcctt gtctctgctg caacgtgcc aattgaaaaa acggaggatg 1080
tatgcacatg aagtgtcttc agccccagtg caagctggag tgggtgctgga actgtggctg 1140
tgagtggaac cgagcctgca tgggagatca ctggtttgac gtgtagagag agatgtcact 1200
tggccctgga cgcacaacct caagggaac tccgaagatt cctaccttc ttagccattt 1260
cttcttctcg atgcatataa gcacataaat gcgcacacac aaacacaggc tgcagattac 1320
agaagcagcc cctagatcct ttctagggca cccacagaaa accacagcac ccgctggccc 1380
cagggggagg aggcacttct agcctctggc tcaactcgaat gtcagagctt agatgagggt 1440
gcacctttgg tttggattct gtagaagcca tgagttaggt ggggaagtgtt ttccagggtt 1500
gttgccacgc cctgggtaag taacacctct gaggtattctc agaagcacac ttgagatctg 1560
aggaacgctg ctctcatgta gtaatcatct attcccaaag ggccccctgc agtagtcaaa 1620
actatttgtt tatcccccca aatcctatct ttacaaatgg tctgatgag attacaacct 1680
ctctgtgtac taatcagctt atcaaccaag tgagaacctt ggaaagctaa ttggatggca 1740
gactgcttaa atcgcaggga ggactcagaa gccaaacctt cttccgttcg ttccattatc 1800
tgcaacttta gaaagaaatg atcttttttt cccctgaaa agataacaaa gtctgcaatt 1860
tggtttggag tattectact gcagcctgga agtttagctt cactgtgaat ttaacagaga 1920
aagtgcctat aaagggggcg tttttaagag acaatcccat gatgctgcgc caatgctaac 1980
aacagggtca agaaacacaa tgtttataga aggagcatcc ctcgaccatc tgaatgagag 2040
tatgcctgac ccttccacc acaagtgggg acacctctgc atatctgctc cctcctctgc 2100
tgttaagccc cagggagccc catccacca gtggtcctac agacagggca atacacacac 2160
accaagatag ccttcagatc aacatgcac acactcaagt gttaatcttt caagggtttt 2220
ttttcttttt cctgtttttt atttgttttg cttttgcttt tttttttttt ttttttgggt 2280
gtggtggggc taccaaactt gaggcctaga gctaaaaatc atatagaaat gatgttatct 2340
tgtggtgtga ggaaaggcca gctggcctaa gttcacactt ttgtccaggt ggccctagac 2400
tccaccagc cagctcccaa aatgaaaaga ccacctgtca agcagcagtc aggagtctga 2460
```

```

tgtaacccat cactatTTTT tttccatcat tgtgtttgcc tctgcttctt tccacacccg 2520
tgtgacgtaa tgcattggg aagccaggac aatgtttgct gttctgcttt gggtaaagg 2580
actccctgaa gctctgtggc tctccagtat ggtccctttt ccttcctaac agatgcatat 2640
gttttcttca gaatacaata gtgattctta aaataaccca aaagacaggc atccacagtg 2700
tgtgagcatg aatcacagcc tgcattgtgt gagtgtgaat agtgggataa aagtggatgt 2760
cagaagagtg gaaatcaaac ctctgcaaag caatctttct ctttctgtga agtgtattaa 2820
gaaatacctg aagtctgtgt gtgtgggtgt acccagactg tcaatcaata aagaccaga 2880
ctgtcaatga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2918

```

<210> 13

<211> 3043

<212> DNA

<213> mouse

<400> 13

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccctctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccagg aggagaagtc 360
atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctgagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggg cattctggac acagacagta agagggattc agaagcagcc agaggtccag 540
ttaaaccac ctacaacagc tttttcatct actgcaaagg cccctgccac aaggtccagc 600
ctggaaagct ccgagttcag tgtggcacct gcaacaagc aacctcacc ttggcccagg 660
gcccattctt ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgccc tggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtccgtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttccca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgctca acttggttac tccctgccgt gtgtagtttg ttttctgccg ggactgtaag 1020
gaagcatacc atgaagggga ttgcgactca ctgctcgaac cctcaggagc cacttctcag 1080
gcctacaggg tggacaaaag agccgctgag caagctcgct gggaggaggc ctccaaggaa 1140
accatcaaga agaccacaa gccttgtcct cgctgcaacg tgccaattga aaaaaacgga 1200
ggatgtatgc acatgaagtg tccctagccc cagtgcgaagc tggagtgggtg ctggaactgt 1260
ggctgtgagt ggaaccgagc ctgcatggga gatcactggt ttgacgtgta gagagagatg 1320
tcaactggcc ctggacgcac aacctcaagg gaaactccga agattcctac cttccttagc 1380
catttcttct tctcgatgca tataagcaca taaatgcgca cacacaaaca caggctgcag 1440
attacagaag cagccctag atcctttcta gggcacccac agaaaaccac agcaccgcgt 1500
ggccccaggg ggaggaggca ctttcagcct ctggctcact cgaatgtcag agcttagatg 1560
aggggtgcacc tttggtttg attctgtaga agccatgagt gaggtgggaa gtgttttcca 1620
gggttgttgc cagccctgg gtaagtaaca cctctgagga ttctcagaag cacacttgag 1680
atctgaggaa cgctgctctc atgtagtaat catctattcc caaaggggcc cctgcagtag 1740
tcaaaactat ttgtttatcc cccaaatcc tatctttaca aatgggtgctg atgagattac 1800
aaccctctg tgtactaatc agcttatcaa ccaagtgaga acctaggaaa gctaattgga 1860
tggcagactg cttaaatcgc agggaggact cagaagccaa acctacttcc gttcgtttca 1920
ttatctgcaa ctttagaaag aaatgatctt tttttcccc tgaaaagata acaaagtctg 1980

```

```

caatttgggtt tggagtattc ctactgcagc ctggaagttt agcttcactg tgaatttaac 2040
agagaaaagtg cctataaagg gggcggtttt aagagacaat cccatgatgc tgcgccaatg 2100
ctaacaacag ggtcaagaaa cacaatgttt atagaaggag catccctcga ccactctgaat 2160
gagagtatgc ctgacccctt ccaccacaag tggggacacc tctgcatatc tgctccctcc 2220
tctgctgtta agccccaggg agccccatcc acccagtggg cctacagaca gggcaatata 2280
cacacaccaa gatagccttc agatcaacat gcatcacact caagtgttaa tctttcaagg 2340
ttttcttttc tttttcctgt tttttatttg ttttgctttt gctttttttt tttttttttt 2400
tggtgggtggg ggggctacca aacttgaggc ctagagctaa aaatcatata gaaatgatgt 2460
tatcttgtgg tgtgaggaaa ggccagctgg cctaagttca cacttttgtc ccagtggccc 2520
tagactccac ccagccagct cccaaaatga aaagaccacc tgtcaagcag cagtcaggag 2580
tctgatgtca cccatcacta ttttttttcc atcattgtgc ttgcctctgc ctccctccac 2640
accctgtgtga cgtaatcgca ttgggaagcc aggacaatgt ttgctgttct gctttgggta 2700
aagggactcc ctgaagctct gtggctctcc agtatggctc cttttccttc ctaacagatg 2760
catatgtttt cttcagaata caatagtgt tcttaaaata acccaaaaga caggcatcca 2820
cagtgtgtga gcatgaatca cagcctgcac tgtgtgagtg tgaatagtgg gataaaagtg 2880
gatgtcagaa gagtggaaat caaacctctg caaagcaatc tttctctttc tgtgaagtgt 2940
attaagaaat acctgaagtc tgtgtgtgtg gtggtaccca gactgtcaat caataaagac 3000
ccagactgtc aatgaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 3043

```

<210> 14

<211> 3253

<212> DNA

<213> mouse

<400> 14

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggg gggcgccagt gcccgcgtag gtccttctcg acccgagcc accaccggc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacgg ggttccagct 240
gaccagctgc gtgtgatttt tgccgggaag gagcttccga atcacctgac ggttcaaaac 300
tgtgacctgg aacaacagag tattgtacac atagtacaga gaccacggag gagaagtcat 360
gaaacaaatg catctggagg ggacgaaccc cagagcacct cagagggctc catatgggag 420
tccaggagct tgacacgagt ggacctgagc agccataccc tgccgggtgga ctctgtgggg 480
ctggcggtca ttctggacac agacagtaag agggattcag aagcagccag aggtccagtt 540
aaacccacct acaacagctt tttcatctac tgcaaaggcc cctgccacaa ggtccagcct 600
ggaaagctcc gagttcagtg tggcacctgc aaacaagcaa ccctcacctt ggcccagggc 660
ccatcttgct gggacgatgt ctttaattcca aaccggatga gtggtgagtg ccagtctcca 720
gactgccctg gaaccagagc tgaatttttc tttaaatgtg gagcacacc aacctcagac 780
aaggacacgt cggtagcttt gaacctgac accagcaaca ggcgagcat cccttgcata 840
gcgtgcacag atgtcaggag ccctgtcctg gtcttccagt gtaaccaccg tcacgtgatc 900
tgtttgagct gtttccactt gtattgtgtc acaagactca acgatcggca gtttgtccac 960
gatgtcaaac ttggctactc cctgccgtgt gtagctggct gtcccaactc cctgattaaa 1020
gagctccatc acttcaggat ccttggagaa gagcagtaca ctaggtacca gcagtatggg 1080
gccgaggaat gcgtgctgca aatgggaggt gtgctgtgcc cccgtcctgg ctgtggagct 1140
ggactgctac ctgaacaggg ccagaggaag gtcacctgcg aagggggcaa cggcctgggc 1200
tgcggttttg ttttctgccg ggactgtaag gaagcatacc atgaagggga ttgcgactca 1260
ctgctcgaac cctcaggagc cacttctcag gcctacaggg tggacaaaag agccgctgag 1320
caagctcgct gggaggaggc ctccaaggaa accatcaaga agaccaccaa gccttgctct 1380

```

```

cgctgcaacg tgccaattga aaaaaacgga ggatgtatgc acatgaagtg tcctcagccc 1440
cagtgcgaagc tggagtgggtg ctggaactgt ggctgtgagt ggaaccgagc ctgcatggga 1500
gatcactgggt ttgacgtgta gagagagatg tcacttggcc ctggacgcac aacctcaagg 1560
gaaactccga agattcctac cttccttagc catttcttct tctcgatgca tataagcaca 1620
taaatgcgca cacacaaaca caggctgcag attacagaag cagcccctag atcctttcta 1680
gggcacccac agaaaaccac agcaccgct ggccccaggg ggaggaggca ctttcagcct 1740
ctggctcact cgaatgtcag agcttagatg aggggtgcacc tttggtttggt attctgtaga 1800
agccatgagt gaggtgggaa gtgtttttcca gggttgttgc cagccctgg gtaagtaaca 1860
cctctgagga ttctcagaag cacacttgag atctgaggaa cgctgctctc atgtagtaat 1920
catctattcc caaagggccc cctgcagtag tcaaaactat ttgtttatcc ccccaaatcc 1980
tatctttaca aatggtgctg atgagattac aaccctctg tgtactaatc agcttatcaa 2040
ccaagtgaga acctaggaaa gctaattgga tggcagactg cttaaatcgc agggaggact 2100
cagaagccaa acctacttcc gttcgtttca ttatctgcaa ctttagaaaag aaatgatctt 2160
tttttcccc tgaaaagata acaaagtctg caatttggtt tggagtattc ctactgcagc 2220
ctggaagttt agcttccactg tgaatttaac agagaaagtg cctataaagg gggcgttttt 2280
aagagacaat cccatgatgc tgcgccaatg ctaacaacag ggtcaagaaa cacaatgttt 2340
atagaaggag catccctcga ccatctgaat gagagtatgc ctgaccctt ccaccacaag 2400
tggggacacc tctgcataac tgctccctcc tctgctgtta agcccaggg agcccatcc 2460
acccagtggg cctacagaca gggcaataca cacacacaa gatagcctt agatcaacat 2520
gcatcacact caagtgttaa tctttcaagg ttttcttttc ttttctctgt tttttatttg 2580
ttttgctttt gctttttttt tttttttttt tgggtgggtgg ggggctacca aacttgagge 2640
ctagagctaa aaatcatata gaaatgatgt tatcttgtgg tgtgaggaaa ggccagctgg 2700
cctaagttca cacttttgtc ccagtggccc tagactccac ccagccagct cccaaaatga 2760
aaagaccacc tgtcaagcag cagtcaggag tctgatgtca cccatcacta ttttttttcc 2820
atcattgtgc ttgcctctgc ctccttccac acccggtgta cgtaatcgca ttgggaagcc 2880
aggacaatgt ttgctgttct gctttgggtg aagggactcc ctgaagctct gtggctctcc 2940
agtatgggtc cttttccttc ctaacagatg catatgtttt cttcagaata caatagtgat 3000
tcttaaaata acccaaaaga caggcatcca cagtgtgtga gcatgaatca cagcctgcat 3060
tgtgtgagtg tgaatagtgg gataaaagtg gatgtcagaa gaggggaaat caaacctctg 3120
caaagcaatc tttctcttcc tgtgaagtgt attaagaaat acctgaagtc tgtgtgtgtg 3180
gtggtaccca gactgtcaat caataaagac ccagactgtc aatgaaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaa

```

3253

<210> 15

<211> 3254

<212> DNA

<213> mouse

<400> 15

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gccgcgtag gtcttctctg accgcagcc accaccgcc 120
cgggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt ttgcccggga aggagcttcc gatcacctga cggttcaaaa 300
ctgtgacctg gaacaacaga gtattgtaca catagtacag agaccacgga ggagaagtca 360
tgaaacaaat gcatctggag gggacgaacc ccagagcacc tcagaggggt ccatatggga 420
gtccaggagc ttgacacgag tggacctgag cagccatacc ctgccgggtg actctgtggg 480
gctggcggtc attctggaca cagacagtaa gagggattca gaagcagcca gaggtccagt 540

```

```

taaaccacc tacaacagct ttttcatcta ctgcaaaggc ccttgccaca aggtccagcc 600
tggaagctc cgagttcagt gtggcacctg caaacaagca accctcacct tggcccaggg 660
cccattcttc tgggacgatg tcttaattcc aaaccggatg agtgggtgagt gccagtctcc 720
agactgccct ggaaccagag ctgaattttt ctttaaagtgt ggagcacacc caacctcaga 780
caaggacacg tcggtagctt tgaacctgat caccagcaac aggcgcagca tcccttgcat 840
agcgtgcaca gatgtcagga gccctgtcct ggtcttccag tgtaaccacc gtcacgtgat 900
ctgtttggac tgtttccact tgtattgtgt cacaagactc aacgatcggc agtttgtcca 960
cgatgctcaa cttggctact ccttgccgtg tgtagctggc tgtcccaact ccttgattaa 1020
agagctccat cacttcagga tccttggaga agagcagtac actaggtagc agcagtatgg 1080
ggccgaggaa tgcgtgctgc aaatgggagg tgtgctgtgc ccccgctcctg gctgtggagc 1140
tggaactgcta cctgaacagg gccagaggaa agtcacctgc gaagggggca acggcctggg 1200
ctgcgggttt gttttctgcc gggactgtaa ggaagcatac catgaagggg attgcgactc 1260
actgctcgaa cctcaggag ccacttctca ggcctacagg gtggacaaaa gagccgctga 1320
gcaagctcgc tgggaggagg cctccaagga aaccatcaag aagaccacca agccttgtec 1380
tcgctgcaac gtgccaattg aaaaaaacgg aggatgtatg cacatgaagt gtcctcagcc 1440
ccagtgcagg ctggagtggg gctggaactg tggctgtgag tggaaaccgag cctgcatggg 1500
agatcactgg tttgacgtgt agagagagat gtcacttggc cctggacgca caacctcaag 1560
ggaaactccg aagattccta ccttccttag ccatttcttc ttctcgatgc atataagcac 1620
ataaatgcgc acacacaaac acaggctgca gattacagaa gcagcccta gatcctttct 1680
agggcaccca cagaaaacca cagcacccgc tggccccagg gggaggaggc actttcagcc 1740
tctggctcac tcgaatgtca gagcttagat gaggtgcac ctttgggttg gattctgtag 1800
aagccatgag tgagggtggg agtgttttcc agggttgttg ccacgccctg ggtaagtaac 1860
acctctgagg attctcagaa gcacacttga gatctgagga acgctgctct catgtagtaa 1920
tcattctatc ccaaagggcc cctgcagta gtcaaaacta tttgtttatc ccccaaatc 1980
ctattctttac aaatgggtgt gatgagatta caaccctct gtgtactaat cagcttatca 2040
accaagtgag aacctaggaa agctaattgg atggcagact gcttaaactg caggaggagc 2100
tcagaagcca aacctacttc cgttcgtttc attatctgca actttagaaa gaaatgatct 2160
ttttttcccc ctgaaaagat aacaaagtct gcaatttggg ttggagtatt cctactgcag 2220
cctggaagtt tagcttcact gtgaatttaa cagagaaagt gcctataaag ggggcgtttt 2280
taagagacaa tcccatgatg ctgcgccaat gctaacaaca gggtaagaa acacaatgtt 2340
tatagaagga gcatccctcg accatctgaa tgagagtatg cctgaccctc tccaccacaa 2400
gtggggacac ctctgcatat ctgctccctc ctctgctgtt aagccccagg gagccccatc 2460
caccagtggt tctacagac agggcaatac acacacacca agatagcctt cagatcaaca 2520
tgcatcacac tcaagtgtta atctttcaag gttttctttt ctttttctctg ttttttattt 2580
gttttgcctt tgcctttttt tttttttttt ttgggtgggtg tggggctacc aaacttgagg 2640
cctagagcta aaaatcatat agaaatgatg ttatcttgtg gtgtgaggaa aggccagctg 2700
gcctaagttc acacttttgt cccagtggtc ctagactcca cccagccagc tcccaaatg 2760
aaaagaccac ctgtcaagca gcagtcagga gtctgatgtc accatcact attttttttc 2820
catcattgtg cttgcctctg cctccttcca caccgtgtg acgtaatgc attgggaagc 2880
caggacaatg tttgctgttc tgctttgggt aaagggactc cctgaagctc tgtggctctc 2940
cagtatggtc ctttttctt cctaacagat gcatatgttt tcttcagaat acaatagtga 3000
ttcttaaaat aacccaaaag acaggcatcc acagtgtgtg agcatgaatc acagcctgca 3060
ttgtgtgagt gtgaatagtg ggataaaagt ggatgtcaga agagtggaaa tcaaacctct 3120
gcaaagcaat ctttctcttt ctgtgaagtg tattaagaaa tacctgaagt ctgtgtgtgt 3180
gggtgtaccc agactgtcaa tcaataaaga cccagactgt caatgaaaaa aaaaaaaaaa 3240
aaaaaaaaa aaaa

```

3254

<211> 3253

<212> DNA

<213> mouse

<400> 16

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gccgcgtag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggagggtcg 180
attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg gagaagtcac 360
gaaacaaatg catctggagg ggacgaaccc cagagcacct cagagggctc catatgggag 420
tccaggagct tgacacgagt ggacctgagc agccataccc tggcgggtgga ctctgtgggg 480
ctggcgggtca ttctggacac agacagtaag agggattcag aagcagccag aggtccagtt 540
aaaccacact acaacagctt tttcatctac tgcaaaggcc cctgccacaa ggtccagcct 600
ggaaagctcc gagttcagtg tggcacctgc aaacaagcaa cctcacctt ggcccagggc 660
ccatcttgct gggacgatgt cttaattcca aaccggatga gtggtgagtg ccagtctcca 720
gactgccctg gaaccagagc tgaatttttc tttaaatgtg gagcacaccc aacctcagac 780
aaggacacgt cggtagcttt gaacctgac accagcaaca ggcgcagcat cccttgcata 840
gcgtgcacag atgtcaggag ccctgtcctg gtcttccagt gtaaccaccg tcacgtgac 900
tgtttggaact gtttccactt gtattgtgtc acaagactca acgatcgga gtttgtccac 960
gatgctcaac ttggctactc cctgccgtgt gtagctgggt gtcccaactc cctgattaaa 1020
gagctccatc acttcaggat ccttgagaa gagcagtaca ctaggtacca gcagtatggg 1080
gccgaggaat gcgtgctgca aatgggaggt gtgctgtgcc cccgtcctgg ctgtggagct 1140
ggactgctac ctgaacaggg ccagaggaaa gtcacctgcg aagggggcaa cggcctgggc 1200
tgccgggtttg ttttctgccg ggactgtaag gaagcatacc atgaagggga ttgcgactca 1260
ctgctcgaac cctcaggagc cacttctcag gcctacaggg tggacaaaag agccgctgag 1320
caagctcgct gggaggaggc ctccaaggaa accatcaaga agaccaccaa gccttgtcct 1380
cgctgcaacg tgccaattga aaaaaacgga ggatgtatgc acatgaagtg tcctcagccc 1440
cagtgcagc tggagtgggt ctggaactgt ggctgtgagt ggaaccgagc ctgcatggga 1500
gatcactggg ttgacgtgta gagagagatg tcacttggcc ctggacgcac aacctcaagg 1560
gaaactccga agattcctac cttecttagc catttcttct tctcgatgca tataagcaca 1620
taaattgcga cacacaaaca caggctgcag attacagaag cagccccatg atcctttcta 1680
gggcacccac agaaaaccac agcaccgct ggccccaggg ggaggaggca ctttcagcct 1740
ctggctcact cgaatgtcag agcttagatg aggggtgcacc tttggtttgg attctgtaga 1800
agccatgagt gaggtgggaa gtgttttcca gggttgttgc cacgccctgg gtaagtaaca 1860
cctctgagga ttctcagaag cacacttgag atctgaggaa cgctgctctc atgtagtaat 1920
catctattcc caaagggccc cctgcagtag tcaaaactat ttgtttatcc ccccaaatcc 1980
tatctttaca aatgggtgctg atgagattac aaccctctg tgtactaatc agcttatcaa 2040
ccaagtgaga acctaggaaa gctaattgga tggcagactg cttaaactgc agggaggact 2100
cagaagccaa acctacttcc gttegtttca ttatctgcaa ctttagaaaag aaatgatctt 2160
tttttcccc tgaaaagata acaaagtctg caatttggtt tggagtattc ctactgcagc 2220
ctggaagttt agcttcaactg tgaatttaac agagaaagt cctataaagg gggcggtttt 2280
aagagacaat cccatgatgc tgcgccaatg ctaacaacag ggtcaagaaa cacaatgttt 2340
atagaaggag catccctcga ccacttgaat gagagtatgc ctgacccctt ccaccacaag 2400
tggggacacc tctgcatatc tgetccctcc tctgctgtta agccccaggg agccccatcc 2460
accagtggt cctacagaca gggcaatata cacacaccaa gatagccttc agatcaacat 2520
gcacacact caagtgttaa tctttcaagg ttttcttttc ttttccctgt tttttatttg 2580


```

ttttgctttt gctttttttt tttttttttt tgggtgggtgg ggggctacca aacttgaggc 2640
ctagagctaa aaatcatata gaaatgatgt tatcttgtgg tgtgaggaaa ggccagctgg 2700
cctaagtcca cacttttgtc ccagtggccc tagactccac ccagccagct cccaaaatga 2760
aaagaccacc tgtcaagcag cagtcaggag tctgatgtca cccatcacta ttttttttcc 2820
atcattgtgc ttgcctctgc ctccttccac acccgtgtga cgtaatcgca ttgggaagcc 2880
aggacaatgt ttgctgttct gctttgggta aagggaactcc ctgaagctct gtggctctcc 2940
agtatgggcc cttttccttc ctaacagatg catatgtttt cttcagaata caatagtgat 3000
tcttaaaata acccaaaaga caggcatcca cagtgtgtga gcatgaatca cagcctgcat 3060
tgtgtgagtg tgaatagtg gataaaagt gatgtcagaa gaggtgaaat caaacctctg 3120
caaagcaatc tttctcttcc tgtgaagtgt attaagaaat acctgaagtc tgtgtgtgtg 3180
gtggtaccca gactgtcaat caataaagac ccagactgtc aatgaaaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaa

```

3253

<210> 17

<211> 3092

<212> DNA

<213> mouse

<400> 17

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accaccgcc 120
cggtgaccat gatagtaact gtgacctgga acaacagagt attgtacaca tagtacagag 180
accacggagg agaagtcacg aaacaaatgc atctggaggg gacgaacccc agagcacctc 240
agagggctcc atatgggagt ccaggagctt gacacgagtg gacctgagca gccataccct 300
gccggtggac tctgtggggc tggcggtcat tctggacaca gacagtaaga gggattcaga 360
agcagccaga ggtccagtta aaccaccta caacagcttt ttcactctact gcaaaggccc 420
ctgccacaag gtccagcctg gaaagctccg agttcagtggt ggcacctgca aacaagcaac 480
ctcacccttg gccagggcc catcttgctg ggacgatgtc ttaattccaa accggatgag 540
tgggtgagtg cagtctccag actgccctgg aaccagagct gaatttttct ttaaatgtgg 600
agcacacca acctcagaca aggacacgac ggtagctttg aacctgatca ccagcaacag 660
gcgcagcatc ccttgcatag cgtgcacaga tgtcaggagc cctgtcctgg tcttccagtg 720
taaccaccgt cacgtgatct gtttggactg tttccacttg tattgtgtca caagactcaa 780
cgatcggcag tttgtccacg atgctcaact tggctactcc ctgccgtgtg tagctggctg 840
tcccaactcc ctgattaaag agctccatca ctccaggatc cttggagaag agcagtacac 900
taggtaccag cagtatgggg ccgaggaatg cgtgctgcaa atgggaggtg tgcgtgtgcc 960
ccgtcctggc tgtggagctg gactgctacc tgaacagggc cagaggaaag tcacctgcga 1020
agggggcaac ggcctgggct gcgggtttgt tttctgccgg gactgtaagg aagcatacca 1080
tgaaggggat tgcgactcac tgctcgaacc ctcaggagcc acttctcagg cctacagggt 1140
ggacaaaaga gccgctgagc aagctcgctg ggaggaggcc tccaaggaaa ccatcaagaa 1200
gaccaccaag ccttgtcctc gctgcaacgt gccaattgaa aaaaacggag gatgtatgca 1260
catgaagtgt cctcagcccc agtgcaagct ggagtggtgc tggaaactgtg gctgtgagtg 1320
gaaccgagcc tgcattggag atcactggtt tgacgtgtag agagagatgt cacttggccc 1380
tggacgcaca acctcaaggg aaactccgaa gattcctacc ttccttagcc atttcttctt 1440
ctcgatgcat ataagcacat aaatgcgcac acacaaacac aggctgcaga ttacagaagc 1500
agcccctaga tcttttctag ggcaccaca gaaaaccaca gcaccgctg gccccagggg 1560
gaggaggcac tttcagcctc tggctcactc gaatgtcaga gcttagatga ggggtgcacct 1620
ttggtttgga ttctgtagaa gccatgagtg aggtgggaag tgttttccag ggttgttgcc 1680
acgccttggg taagtaacac ctctgaggat tctcagaagc acacttgaga tctgaggaac 1740

```

```

gctgctctca tgtagtaatc atctattccc aaagggcccc ctgcagtagt caaaactatt 1800
tgtttatccc cccaaatcct atctttacaa atgggtgctga tgagattaca acccctctgt 1860
gtactaatca gcttatcaac caagtgaagaa cctaggaaag ctaattggat ggcagactgc 1920
ttaaatcgca gggaggactc agaagccaaa cctacttccg ttcgtttcat tatctgcaac 1980
tttagaaaga aatgatcttt tttccccct gaaaagataa caaagtctgc aatttggttt 2040
ggagtattcc tactgcagcc tggaagttta gcttactgt gaatttaaca gagaaagtgc 2100
ctataaaggg ggcgttttta agagacaatc ccatgatgct gcgccaatgc taacaacagg 2160
gtcaagaaac acaatgttta tagaaggagc atccctcgac catctgaatg agagtatgcc 2220
tgacccttc caccacaagt ggggacacct ctgcatatct gctccctcct ctgctgttaa 2280
gccccagggg gccccatcca cccagtggtc ctacagacag ggcaatacac acacaccaag 2340
atagccttca gatcaacatg catcacactc aagtgttaat ctttcaagg tttctttct 2400
tttccctgtt ttttatttgt tttgcttttg cttttttttt tttttttttt ggtgggtggg 2460
gggctaccaa acttgaggcc tagagctaaa aatcatatag aaatgatgtt atcttgtggt 2520
gtgaggaaag gccagctggc ctaagttcac acttttgtcc cagtggccct agactccacc 2580
cagccagctc ccaaaatgaa aagaccacct gtcaagcagc agtcaggagt ctgatgtcac 2640
ccatcactat tttttttcca tcattgtgct tgccctctgc tccttcaca cccgtgtgac 2700
gtaatcgcat tgggaagcca ggacaatgtt tgctgttctg ctttgggtaa agggactccc 2760
tgaagctctg tggctctcca gtatggctcc ttttccctcc taacagatgc atatgttttc 2820
ttcagaatac aatagtgtt cttaaaataa cccaaaagac aggcattcac agtgtgtgag 2880
catgaatcac agcctgcatt gtgtgagtgt gaatagtggg ataaaagtgg atgtcagaag 2940
agtggaaatc aaacctctgc aaagcaatct ttctctttct gtgaagtgt ttaagaaata 3000
cctgaagtct gtgtgtgtgg tggtagccag actgtcaatc aataaagacc cagactgtca 3060
atgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa

```

3092

<210> 18

<211> 3255

<212> DNA

<213> mouse

<400> 18

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gccgcgctag gtccttctcg acccgagcc accaccggc 120
cggtgacct gatagtgtt gtcaggttca actccagcta tggcttccca gtggaggtcg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240
ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
actgtgacct ggaacaacag agtattgtac acatagtaca gagaccagc aggagaagtc 360
atgaaacaaa tgcatctgga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
agtccaggag cttgacacga gtggacctga gcagccatac cctgccggtg gactctgtgg 480
ggctggcggt cattctggac acagacagta agagggatc agaagcagcc agagggtccag 540
ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
ctggaaatct ccgagttcag tgtggcacct gcaaacaagc aacctcacc ttggcccagg 660
gccccctctg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtctc 720
cagactgcc tggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
tagcgtgcac agatgtcagg agccctgtcc tggcttccca gtgtaaccac cgtcacgtga 900
tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
acgatgtca acttggtac tcctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
aagagctcca tcaattcagg atccttggag aagagcagta cactaggtac cagcagtatg 1080

```

```

gggccgagga atgctgtctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140
ctggaactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
gctgcggggtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgcgact 1260
cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgtc 1380
ctcgttgcaa cgtgccaaatt gaaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440
cccagtgcga gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1500
gagatcactg gtttgactg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560
gggaaactcc gaagattcct accttcttta gccatttctt cttctcgatg catataagca 1620
cataaatgcg cacacacaaa cacaggctgc agattacaga agcagccccc agatcctttc 1680
tagggcaccc acagaaaacc acagcacccg ctggcccccag ggggaggagg cacttttcagc 1740
ctctggctca ctcgaaatgtc agagcttaga tgagggtgca cctttgggtt ggattctgta 1800
gaagccatga gtgagggtggg aagtgttttc cagggttgtt gccacgcccc gggtaagtaa 1860
cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcctgtagta 1920
atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat ccccccaat 1980
cctatcttta caaatggtgc tgatgagatt acaacccctc tgtgtactaa tcagcttatc 2040
aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaatc gcagggagga 2100
ctcagaagcc aaacctactt ccgttcgttt cattatctgc aacttttaga agaaatgatc 2160
tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tcctactgca 2220
gcctggaagt ttagcttcac tgtgaattta acagagaaag tgcctataaa gggggcgttt 2280
ttaagagaca atcccatgat gctgcgccaa tgctaacaac agggtaaga aacacaatgt 2340
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2400
agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccct 2460
ccaccagtg gtccacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520
atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580
tgttttgctt ttgttttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tcccagtggc cctagactcc acccagccag ctcccaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tatttttttt 2820
ccatcattgt gcttgctctt gcctccttcc acaccctgt gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940
ccagtatggt cctttttcct tcctaacaga tgcataatgt ttcttcagaa tacaatagt 3000
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gacatgaat cacagcctgc 3060
attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 3120
tgcaaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaaaa

```

3255

<210> 19

<211> 3255

<212> DNA

<213> mouse

<400> 19

```

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
aggctcgggc gggcgccagt gccgcgtag gtccttctcg acccgagcc accaccgccc 120
cggtgacct gatagtgttt gtcaggttca actccagcta tggcttccca gtggaggctg 180
attctgacac cagcatcttg cagctcaagg aagtggttgc taagcgacag ggggttccag 240

```

ctgaccagct gcggtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
 actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
 atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
 agtccaggag cttgacacga gtggacctga gcagccatac cctgccgggtg gactctgtgg 480
 ggctggcggt cattctggac acagacagta agagggatc agaagcagcc agagggtccag 540
 ttaaaccacac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
 ctggaaagct ccgagttcag tgtggcacct gcaaacaagc aaccctcacc ttggcccagg 660
 gcccattctg ctgggacgat gtcttaattc caaacccgat gagtgggtgag tgccagtctc 720
 cagactgccc tgggaaccaga gctgaatttt tctttaaatg tggagcacac ccaacctcag 780
 acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
 tagcgtgcac agatgtcagg agccctgtcc tggctctcca gtgtaaccac cgtcacgtga 900
 tctgttttga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
 acgatgctca acttggtctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
 aagagctcca tcacttcagg atccttgagg aagagcagta cactaggtag cagcagtatg 1080
 gggccgagga atgctgtctg caaatgggag gtgtgctgtg cccctgtcct ggctgtggag 1140
 ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
 gctgcccgtt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgagact 1260
 cactgctcga accctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
 agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccaac aagccttgct 1380
 ctgctgcaa cgtgccatt gaaaaaacg gaggatgtat gcacatgaag tgtcctcagc 1440
 cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtggaaccga gcctgcatgg 1500
 gagatcactg gtttgacgtg tagagagaga tgtcacttgg ccctggacgc acaacctcaa 1560
 gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620
 cataaatgag cacacacaaa cacaggctgc agattacaga agcagccctc agatcctttc 1680
 tagggcaccc acagaaaacc acagcacccg ctggccccag ggggaggagg cactttcagc 1740
 ctctggctca ctcgaaatgtc agagcttaga tgagggtgca cctttggtt ggattctgta 1800
 gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860
 cacctctgag gattctcaga agcacacttg agatctgagg aacgctgtct tcatgtagta 1920
 atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat ccccccaat 1980
 cctatcttta caaatggtgc tgatgagatt acaaccctc tgtgtactaa tcagcttatt 2040
 aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaatc gcaggagga 2100
 ctgagaagcc aaacctactt ccgttcgttt cattatctgc aactttagaa agaaatgatc 2160
 ttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tctactgca 2220
 gcctggaagt ttagcttcac tgtgaattta acagagaaag tgccataaa gggggcgttt 2280
 ttaagagaca atcccatgat gctgcgccaa tgctaacaac agggtaaga aacacaatgt 2340
 ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttcaccaca 2400
 agtggggaca cctctgcata tctgtccct cctctgctgt taagccccag ggagccccat 2460
 ccaccagtg gtctacaga cagggaata cacacacacc aagatagcct tcagatcaac 2520
 atgcatcaca ctcaagtgtt aatctttcaa ggttttctt tcttttctc gttttttatt 2580
 tgttttgctt ttgtttttt ttttttttt tttgggtgtg gtggggctac caaacttgag 2640
 gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
 ggccataagt cacacttttg tccagtggt cctagactcc acccagccag ctcccaaat 2760
 gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tattttttt 2820
 ccatcattgt gcttgccctc gcctccttc acaccctgtg gacgtaatcg cattgggaag 2880
 ccaggacaat gtttgcgtgt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940
 ccagtatggt ccttttctc tccaaacaga tgcattatgt ttcttcagaa tacaatagt 3000
 attcttaaaa taacccaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060
 attgtgtgag tgtgaatagt gggataaaag tggatgtcag aagagtggaa atcaaacctc 3120

tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
 tgggtgtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
 aaaaaaaaaa aaaaaa 3255

<210> 20

<211> 3255

<212> DNA

<213> mouse

<400> 20

ctcagcgagg ggaaggggga ggaggcctgg atgactaaac ctgacagaaa cgctgggtggg 60
 aggctcgggc gggcgccagt gcccgcgtag gtccttctcg acccgagcc accaccgccc 120
 cggtgaccat gatagtgttt gtcaggttca actccagcta tggcttccca gtggagggtcg 180
 attctgacac cagcatcttg cagctcaagg aagtgggtgc taagcgacag ggggttccag 240
 ctgaccagct gcgtgtgatt tttgccggga aggagcttcc gaatcacctg acggttcaaa 300
 actgtgacct ggaacaacag agtattgtac acatagtaca gagaccacgg aggagaagtc 360
 atgaaacaaa tgcattctgga ggggacgaac cccagagcac ctcagagggc tccatatggg 420
 agtccaggag cttgacacga gtggacctga gcagccatac cctgccgggtg gactctgtgg 480
 ggctggcggt cattctggac acagacagta agagggatc agaagcagcc agagggtccag 540
 ttaaacccac ctacaacagc tttttcatct actgcaaagg cccctgccac aagggtccagc 600
 ctggaaagct ccgagttcag tgtggcacct gcaaacaaagc aacctcacc ttggcccagg 660
 gcccatcttg ctgggacgat gtcttaattc caaacggat gagtgggtgag tgccagtcctc 720
 cagactgccc tggaaaccaga gctgaatttt tcttttaaatg tggagcacac ccaacctcag 780
 acaaggacac gtcggtagct ttgaacctga tcaccagcaa caggcgagc atcccttgca 840
 tagcgtgcac agatgtcagg agccctgtcc tggcttccca gtgtaaccac cgtcacgtga 900
 tctgtttgga ctgtttccac ttgtattgtg tcacaagact caacgatcgg cagtttgtcc 960
 acgatgctca acttggctac tccctgccgt gtgtagctgg ctgtcccaac tccctgatta 1020
 aagagctcca tcacttcagg atccttggag aagagcagta cactaggtag cagcagtagt 1080
 gggccgagga atgcgtgctg caaatgggag gtgtgctgtg ccccgctcct ggctgtggag 1140
 ctggactgct acctgaacag ggccagagga aagtcacctg cgaagggggc aacggcctgg 1200
 gctgcggggt tgttttctgc cgggactgta aggaagcata ccatgaaggg gattgagact 1260
 cactgctcga acctcagga gccacttctc aggcctacag ggtggacaaa agagccgctg 1320
 agcaagctcg ctgggaggag gcctccaagg aaaccatcaa gaagaccacc aagccttgctc 1380
 ctgctgcaa cgtgccaatt gaaaaaacg gaggatgtat gcacatgaag tgcctcagc 1440
 cccagtgcaa gctggagtgg tgctggaact gtggctgtga gtagaaccga gcctgcatgg 1500
 gagatcactg gtttgacgtg tagagagaga tgtcacttgg cctggagcg acaacctcaa 1560
 gggaaactcc gaagattcct accttcctta gccatttctt cttctcgatg catataagca 1620
 cataaatgag cacacacaaa cacaggctgc agattacaga agcagccctc agatccttctc 1680
 tagggcaccc acagaaaacc acagcacccg ctggccccag ggggaggagg cactttcagc 1740
 ctctggctca ctggaatgtc agagcttaga tgagggtgca cctttgggtt ggattctgta 1800
 gaagccatga gtgagggtgg aagtgttttc cagggttgtt gccacgccct gggtaagtaa 1860
 cacctctgag gattctcaga agcacacttg agatctgagg aacgctgctc tcatgtagta 1920
 atcatctatt cccaaagggc cccctgcagt agtcaaaact atttgtttat ccccccaat 1980
 cctatcttta caaatggtgc tgatgagatt acaaccctc tgtgtactaa tcagcttctc 2040
 aaccaagtga gaacctagga aagctaattg gatggcagac tgcttaaate gcaggaggga 2100
 ctcagaagcc aaacctactt ccgttcgttt cattatctgc aactttagaa agaaatgatc 2160
 tttttttccc cctgaaaaga taacaaagtc tgcaatttgg tttggagtat tctactgca 2220
 gcctggaagt ttagcttca tgtgaattta acagagaaag tgcctataaa gggggcggtt 2280

```

ttaagagaca atcccatgat gctgcgccaa tgctaacaac aggggtcaaga aacacaatgt 2340
ttatagaagg agcatccctc gaccatctga atgagagtat gcctgacccc ttccaccaca 2400
agtggggaca cctctgcata tctgtccct cctctgtgt taagccccag ggagccccat 2460
ccaccagtg gtcctacaga cagggcaata cacacacacc aagatagcct tcagatcaac 2520
atgcatcaca ctcaagtgtt aatctttcaa ggttttcttt tctttttcct gttttttatt 2580
tgttttgctt ttgctttttt tttttttttt tttgggtgtg gtggggctac caaacttgag 2640
gcctagagct aaaaatcata tagaaatgat gttatcttgt ggtgtgagga aaggccagct 2700
ggcctaagtt cacacttttg tcccagtggc cctagactcc acccagccag ctcccaaaat 2760
gaaaagacca cctgtcaagc agcagtcagg agtctgatgt caccatcac tttttttttt 2820
ccatcattgt gcttgctctt gctccttcc acaccgtgt gacgtaatcg cattgggaag 2880
ccaggacaat gtttgctgtt ctgctttggg taaagggact ccctgaagct ctgtggctct 2940
ccagtatggt cccttttctt tcctaacaga tgcataatgt ttcttcagaa tacaatagt 3000
attcttaaaa taacccaaaa gacaggcatc cacagtgtgt gagcatgaat cacagcctgc 3060
attgtgtgag tgtgaatagt gggataaaaag tggatgtcag aagagtggaa atcaaacctc 3120
tgcaaagcaa tctttctctt tctgtgaagt gtattaagaa atacctgaag tctgtgtgtg 3180
tggtggtacc cagactgtca atcaataaag acccagactg tcaatgaaaa aaaaaaaaaa 3240
aaaaaaaaaa aaaaaa

```

3255

<210> 21

<211> 105

<212> PRT

<213> mouse

<400> 21

```

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
  1              5              10              15

```

```

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
      20              25              30

```

```

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
      35              40              45

```

```

Glu Leu Pro Asn His Leu Thr Val Gln Leu Asn Pro Pro Thr Thr Ala
      50              55              60

```

```

Phe Ser Ser Thr Ala Lys Ala Pro Ala Thr Arg Ser Ser Leu Glu Ser
      65              70              75              80

```

```

Ser Glu Phe Ser Val Ala Pro Ala Asn Lys Gln Pro Ser Pro Trp Pro
      85              90              95

```

```

Arg Ala His Leu Ala Gly Thr Met Ser
      100              105

```

<210> 22

<211> 344
 <212> PRT
 <213> mouse

<400> 22

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Gly Pro Ser Cys Trp Asp Asp
 50 55 60

Val Leu Ile Pro Asn Arg Met Ser Gly Glu Cys Gln Ser Pro Asp Cys
 65 70 75 80

Pro Gly Thr Arg Ala Glu Phe Phe Phe Lys Cys Gly Ala His Pro Thr
 85 90 95

Ser Asp Lys Asp Thr Ser Val Ala Leu Asn Leu Ile Thr Ser Asn Arg
 100 105 110

Arg Ser Ile Pro Cys Ile Ala Cys Thr Asp Val Arg Ser Pro Val Leu
 115 120 125

Val Phe Gln Cys Asn His Arg His Val Ile Cys Leu Asp Cys Phe His
 130 135 140

Leu Tyr Cys Val Thr Arg Leu Asn Asp Arg Gln Phe Val His Asp Ala
 145 150 155 160

Gln Leu Gly Tyr Ser Leu Pro Cys Val Ala Gly Cys Pro Asn Ser Leu
 165 170 175

Ile Lys Glu Leu His His Phe Arg Ile Leu Gly Glu Glu Gln Tyr Thr
 180 185 190

Arg Tyr Gln Gln Tyr Gly Ala Glu Glu Cys Val Leu Gln Met Gly Gly
 195 200 205

Val Leu Cys Pro Arg Pro Gly Cys Gly Ala Gly Leu Leu Pro Glu Gln
 210 215 220

Gly Gln Arg Lys Val Thr Cys Glu Gly Gly Asn Gly Leu Gly Cys Gly

225 230 235 240
 Phe Val Phe Cys Arg Asp Cys Lys Glu Ala Tyr His Glu Gly Asp Cys
 245 250 255
 Asp Ser Leu Leu Glu Pro Ser Gly Ala Thr Ser Gln Ala Tyr Arg Val
 260 265 270
 Asp Lys Arg Ala Ala Glu Gln Ala Arg Trp Glu Glu Ala Ser Lys Glu
 275 280 285
 Thr Ile Lys Lys Thr Thr Lys Pro Cys Pro Arg Cys Asn Val Pro Ile
 290 295 300
 Glu Lys Asn Gly Gly Cys Met His Met Lys Cys Pro Gln Pro Gln Cys
 305 310 315 320
 Lys Leu Glu Trp Cys Trp Asn Cys Gly Cys Glu Trp Asn Arg Ala Cys
 325 330 335
 Met Gly Asp His Trp Phe Asp Val
 340

<210> 23
 <211> 63
 <212> PRT
 <213> mouse

<400> 23
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45
 Glu Leu Pro Asn His Leu Thr Val Gln Leu Ala Val Pro Thr Pro
 50 55 60

<210> 24
 <211> 153
 <212> PRT
 <213> mouse

<400> 24

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Gly Pro Ile Leu Leu Gly Arg
 130 135 140

Cys Leu Asn Ser Lys Pro Asp Glu Trp
 145 150

<210> 25

<211> 194

<212> PRT

<213> mouse

<400> 25

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln

50 55 60
 Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80
 Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95
 Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser
 130 135 140
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys
 145 150 155 160
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala
 165 170 175
 Gln Asn Phe Ser Leu Asn Val Glu His Thr Gln Pro Gln Thr Arg Thr
 180 185 190
 Arg Arg

<210> 26
 <211> 183
 <212> PRT
 <213> mouse

<400> 26
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15
 Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30
 Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45
 Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys
 145 150 155 160

Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala
 165 170 175

Gln Leu Ala Val Pro Thr Pro
 180

<210> 27

<211> 296

<212> PRT

<213> mouse

<400> 27

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110
 Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125
 Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser
 130 135 140
 Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys
 145 150 155 160
 Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala
 165 170 175
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser
 180 185 190
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe
 195 200 205
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala
 210 215 220
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys
 225 230 235 240
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His
 245 250 255
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn
 260 265 270
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys
 275 280 285
 Val Val Cys Phe Leu Pro Gly Leu
 290 295

<210> 28
 <211> 37
 <212> PRT
 <213> mouse

<400> 28

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu

1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
20 25 30

Arg Arg Gly Ser Ser
35

<210> 29
<211> 53
<212> PRT
<213> mouse

<400> 29
Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
35 40 45

Glu Leu Pro Ile Thr
50

<210> 30
<211> 77
<212> PRT
<213> mouse

<400> 30
Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Glu Lys Ser
65 70 75

<210> 31
 <211> 14
 <212> PRT
 <213> mouse

<400> 31
 Met Ile Val Thr Val Thr Trp Asn Asn Arg Val Leu Tyr Thr
 1 5 10

<210> 32
 <211> 464
 <212> PRT
 <213> mouse

<400> 32
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Asn
 145 150 155 160

Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala
 165 170 175
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser
 180 185 190
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe
 195 200 205
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala
 210 215 220
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys
 225 230 235 240
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His
 245 250 255
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn
 260 265 270
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys
 275 280 285
 Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg
 290 295 300
 Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu
 305 310 315 320
 Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys
 325 330 335
 Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu
 340 345 350
 Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys
 355 360 365
 Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly
 370 375 380
 Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala
 385 390 395 400
 Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro
 405 410 415

Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His
 420 425 430

Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys
 435 440 445

Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val
 450 455 460

<210> 33
 <211> 464
 <212> PRT
 <213> mouse

<400> 33
 Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys
 145 150 155 160

Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala
 165 170 175
 Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser
 180 185 190
 Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe
 195 200 205
 Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala
 210 215 220
 Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys
 225 230 235 240
 Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His
 245 250 255
 Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn
 260 265 270
 Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys
 275 280 285
 Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg
 290 295 300
 Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu
 305 310 315 320
 Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys
 325 330 335
 Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu
 340 345 350
 Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys
 355 360 365
 Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly
 370 375 380
 Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala
 385 390 395 400
 Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Asn Lys Pro
 405 410 415

Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His
 420 425 430

Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys
 435 440 445

Gly Cys Glu Trp Asn Arg Ala Cys Met Gly Asp His Trp Phe Asp Val
 450 455 460

<210> 34

<211> 451

<212> PRT

<213> mouse

<400> 34

Met Ile Val Phe Val Arg Phe Asn Ser Ser Tyr Gly Phe Pro Val Glu
 1 5 10 15

Val Asp Ser Asp Thr Ser Ile Leu Gln Leu Lys Glu Val Val Ala Lys
 20 25 30

Arg Gln Gly Val Pro Ala Asp Gln Leu Arg Val Ile Phe Ala Gly Lys
 35 40 45

Glu Leu Pro Asn His Leu Thr Val Gln Asn Cys Asp Leu Glu Gln Gln
 50 55 60

Ser Ile Val His Ile Val Gln Arg Pro Arg Arg Arg Ser His Glu Thr
 65 70 75 80

Asn Ala Ser Gly Gly Asp Glu Pro Gln Ser Thr Ser Glu Gly Ser Ile
 85 90 95

Trp Glu Ser Arg Ser Leu Thr Arg Val Asp Leu Ser Ser His Thr Leu
 100 105 110

Pro Val Asp Ser Val Gly Leu Ala Val Ile Leu Asp Thr Asp Ser Lys
 115 120 125

Arg Asp Ser Glu Ala Ala Arg Gly Pro Val Lys Pro Thr Tyr Asn Ser
 130 135 140

Phe Phe Ile Tyr Cys Lys Gly Pro Cys His Lys Val Gln Pro Gly Lys

145	150	155	160
Leu Arg Val Gln Cys Gly Thr Cys Lys Gln Ala Thr Leu Thr Leu Ala			
165	170	175	
Gln Gly Pro Ser Cys Trp Asp Asp Val Leu Ile Pro Asn Arg Met Ser			
180	185	190	
Gly Glu Cys Gln Ser Pro Asp Cys Pro Gly Thr Arg Ala Glu Phe Phe			
195	200	205	
Phe Lys Cys Gly Ala His Pro Thr Ser Asp Lys Asp Thr Ser Val Ala			
210	215	220	
Leu Asn Leu Ile Thr Ser Asn Arg Arg Ser Ile Pro Cys Ile Ala Cys			
225	230	235	240
Thr Asp Val Arg Ser Pro Val Leu Val Phe Gln Cys Asn His Arg His			
245	250	255	
Val Ile Cys Leu Asp Cys Phe His Leu Tyr Cys Val Thr Arg Leu Asn			
260	265	270	
Asp Arg Gln Phe Val His Asp Ala Gln Leu Gly Tyr Ser Leu Pro Cys			
275	280	285	
Val Ala Gly Cys Pro Asn Ser Leu Ile Lys Glu Leu His His Phe Arg			
290	295	300	
Ile Leu Gly Glu Glu Gln Tyr Thr Arg Tyr Gln Gln Tyr Gly Ala Glu			
305	310	315	320
Glu Cys Val Leu Gln Met Gly Gly Val Leu Cys Pro Arg Pro Gly Cys			
325	330	335	
Gly Ala Gly Leu Leu Pro Glu Gln Gly Gln Arg Lys Val Thr Cys Glu			
340	345	350	
Gly Gly Asn Gly Leu Gly Cys Gly Phe Val Phe Cys Arg Asp Cys Lys			
355	360	365	
Glu Ala Tyr His Glu Gly Asp Cys Asp Ser Leu Leu Glu Pro Ser Gly			
370	375	380	
Ala Thr Ser Gln Ala Tyr Arg Val Asp Lys Arg Ala Ala Glu Gln Ala			
385	390	395	400
Arg Trp Glu Glu Ala Ser Lys Glu Thr Ile Lys Lys Thr Thr Lys Pro			

405

410

415

Cys Pro Arg Cys Asn Val Pro Ile Glu Lys Asn Gly Gly Cys Met His
420 425 430

Met Lys Cys Pro Gln Pro Gln Cys Lys Leu Glu Trp Cys Trp Asn Cys
435 440 445

Gly Cys Glu
450

1633
RECEIVED

JAN 18 2001

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/16176 A3

(51) International Patent Classification⁷: C12N 15/12,
5/10, 1/21, 1/19, C07K 14/47, A01K 67/027, A61K 49/00,
C12Q 1/68

(74) Agent: STERNAGEL, FLEISCHER, GODEMEYER
& PARTNER; Braunsberger Feld 29, D-51429 Bergisch
Gladbach (DE).

(21) International Application Number: PCT/EP00/08071

(81) Designated States (*national*): CA, JP, US.

(22) International Filing Date: 18 August 2000 (18.08.2000)

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(25) Filing Language: English

(26) Publication Language: English

Published:
— with international search report

(30) Priority Data:
99116766.9 30 August 1999 (30.08.1999) EP

(88) Date of publication of the international search report:
27 September 2001

(71) Applicant (*for all designated States except US*):
BIOFRONTERA PHARMACEUTICALS AG
[DE/DE]; Hemmelrather Weg 201, D-51377 Leverkusen
(DE).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): LÜBBERT, Hermann
[DE/DE]; Höhenstrasse 59, D-51381 Leverkusen (DE).



WO 01/16176 A3

(54) Title: TRANSGENIC ANIMAL MODEL FOR NEURODEGENERATIVE DISEASES

(57) Abstract: The present application refers to a mouse parkin2 DNA- and protein sequence, containing mutations or deletions causing Parkinson's disease in a human if occurring in the according human sequence, the construction of a transgenic non-human animal containing such a mutated DNA sequence and therefore expressing no or a less active or non-active parkin protein as well as the use of this transgenic animal as a model for neurodegenerative diseases.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 5807W0	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 00/08071	International filing date (day/month/year) 18/08/2000	(Earliest) Priority Date (day/month/year) 30/08/1999
Applicant BIOFRONTERA PHARMACEUTICALS GMBH et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.


6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08071

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N5/10 C12N1/21 C12N1/19 C07K14/47
 A01K67/027 A61K49/00 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	KESSLER J ET AL: "Investigation of the pathogenic mechanism of parkin mutations" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, pages 52-Abstract 27.20, XP000884113 29th Annual Meeting of the Society for Neuroscience, Part 1, Miami Beach, Florida, USA, October 23-28, 1999 - & DALIE J E (PROGRAM MANAGER - SOCIETY FOR NEUROSCIENCE): "Publication dates for the 1999 Abstract Volumes" SOCIETY FOR NEUROSCIENCE ABSTRACTS, 16 August 1999 (1999-08-16), XP002157614 --- -/--	1-22
L		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

Special categories of cited documents

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

27 February 2001

Date of mailing of the international search report


07/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx 31 651 epo nl
 Fax (+31-70) 340-3016

Authorized officer

Lonnoy, O



C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	<p>DATABASE EMROD E.M.B.L. Databases; Accession Number: AB019558, 13 July 1999 (1999-07-13) SHIMIZU N ET AL: "Mus musculus mRNA for parkin, complete cds" XP002131476 cited in the application 100% identity in 1644 bp overlap with SeqIdNo.1 abstract</p> <p>---</p>	1-22
Y	<p>WO 98 59050 A (JOHNSON WILLIAM G ;LAVEDAN CHRISTIAN (US); NUSSBAUM ROBERT L (US);) 30 December 1998 (1998-12-30) claims 62,63</p> <p>---</p>	8-22
Y	<p>GOLDBERG M S ET AL: "STUDIES OF WILD-TYPE AND MUTANT ALPHA-SYNUCLEIN IN TRANSGENIC MICE" ANNUAL MEETING SOCIETY NEUROSCIENCE,XX,XX, vol. 24, no. 1/02, 1998, page 966 XP000884112 the whole document</p> <p>---</p>	8-22
Y	<p>KITADA ET AL: "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 392, no. 6676, 9 April 1998 (1998-04-09), pages 605-608, XP002108469 ISSN: 0028-0836 cited in the application figure 4C & WO 99 40191 A (SHIMIZU NOBUYOSHI ;MIZUNO YOSHIKUNI (JP)) 12 August 1999 (1999-08-12)</p> <p>---</p>	1-7
Y	<p>LÜCKING ET AL: "Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism" LANCET THE,GB,LANCET LIMITED. LONDON, vol. 352, no. 9137, 24 October 1998 (1998-10-24), pages 1355-1356, XP002108466 ISSN: 0140-6736 cited in the application the whole document</p> <p>---</p> <p style="text-align: center;">-/--</p>	1-7

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	HATTORI ET AL: "Point Mutations (Thr240Arg and Ala311Stop) in the Parkin Gene" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 249, no. 3, 1998, pages 754-758, XP002108468 ISSN: 0006-291X cited in the application figure 1 ---	1-7
Y	LEROY ET AL: "Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease" HUMAN GENETICS,DE,BERLIN, vol. 103, no. 4, October 1998 (1998-10), pages 424-427, XP002108470 cited in the application figure 1 ---	1-7
Y	ABBAS ET AL: "A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe" HUMAN MOLECULAR GENETICS,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 8, no. 4, April 1999 (1999-04), pages 567-574, XP002108471 ISSN: 0964-6906 cited in the application the whole document ---	1-7
Y	HATTORI N ET AL: "Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals" ANN NEUROL., vol. 44, no. 6, December 1998 (1998-12), pages 935-941, XP000877155 cited in the application table 2 ---	1-7
P,X	WO 00 31253 A (INST NAT SANTE RECH MED ;BOULEY SANDRINE (FR); BRICE ALEXIS (FR);) 2 June 2000 (2000-06-02) claims 39,40 -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08071

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9859050	A	30-12-1998	AU	8163798 A	04-01-1999
WO 0031253	A	02-06-2000	FR	2786199 A	26-05-2000
			FR	2797272 A	09-02-2001
			AU	1276900 A	13-06-2000

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

PCT REQUEST

5807WO

Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

0 0-1	For receiving Office use only International Application No.	PCT/EP 00 / 0 8 0 7 1
0-2	International Filing Date	1 8 AUG 2000 (1 8. 08. 2000)
0-3	Name of receiving Office and "PCT International Application"	EUROPEAN PATENT OFFICE PCT INTERNATIONAL APPLICATION
0-4 0-4-1	Form - PCT/RO/101 PCT Request Prepared using	PCT-EASY Version 2.91 (updated 10.05.2000)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	European Patent Office (EPO) (RO/EP)
0-7	Applicant's or agent's file reference	5807WO
I	Title of invention	TRANSGENIC ANIMAL MODEL FOR NEUROGENERATIVE DISEASES
II II-1 II-2 II-4 II-5	Applicant This person is: Applicant for Name Address:	applicant only all designated States except US BIOFRONTERA PHARMACEUTICALS GMBH Hemmelrather Weg 201 D-51377 Leverkusen Germany
II-6 II-7	State of nationality State of residence	DE DE
III-1 III-1-1 III-1-2 III-1-4 III-1-5	Applicant and/or inventor This person is: Applicant for Name (LAST, First) Address:	applicant and inventor US only LÜBBERT, Hermann Höhenstraße 59 D-51381 Leverkusen Germany
III-1-6 III-1-7	State of nationality State of residence	DE DE



PCT REQUEST

5807WO

Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4 0-4-1	Form - PCT/RO/101 PCT Request Prepared using	PCT-EASY Version 2.91 (updated 10.05.2000)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	European Patent Office (EPO) (RO/EP)
0-7	Applicant's or agent's file reference	5807WO
I	Title of invention	TRANSGENIC ANIMAL MODEL FOR NEUROGENERATIVE DISEASES
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	BIOFRONTERA PHARMACEUTICALS GMBH
II-5	Address:	Hemmelrather Weg 201 D-51377 Leverkusen Germany
II-6	State of nationality	DE
II-7	State of residence	DE
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	LÜBBERT, Hermann
III-1-5	Address:	Höhenstraße 59 D-51381 Leverkusen Germany
III-1-6	State of nationality	DE
III-1-7	State of residence	DE



..

.

PCT REQUEST

5807WO

Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name	STERNAGEL, FLEISCHER, GODEMEYER & PARTNER
IV-1-2	Address:	Braunsberger Feld 29 D-51429 Bergisch Gladbach Germany
IV-1-3	Telephone No.	+49-2204-98560
IV-1-4	Facsimile No.	+49-2204-985625
IV-1-5	e-mail	bgl@polypatent.de
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE and any other State which is a Contracting State of the European Patent Convention and of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	CA JP US
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI-1	Priority claim of earlier regional application	
VI-1-1	Filing date	30 August 1999 (30.08.1999)
VI-1-2	Number	99116766.9
VI-1-3	Regional Office	EP
VI-2	Priority document request The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s)	VI-1
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)



PCT REQUEST

5807WO

Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

VII-2	Request to use results of earlier search; reference to that search		
VII-2-1	Date	24 February 2000 (24.02.2000)	
VII-2-2	Number	99 116 766.9	
VII-2-3	Country (or regional Office)	EP	
VIII	Check list	number of sheets	electronic file(s) attached
VIII-1	Request	4	-
VIII-2	Description (excluding sequence listing part)	32	-
VIII-3	Claims	4	-
VIII-4	Abstract	1	5807ep_abstract.txt
VIII-5	Drawings	4	-
VIII-6	Sequence listing part of description	39	-
VIII-7	TOTAL	84	
VIII-8	Accompanying items	paper document(s) attached	electronic file(s) attached
VIII-8	Fee calculation sheet	✓	-
VIII-15	Nucleotide and/or amino acid sequence listing in computer readable form		separate diskette
VIII-16	PCT-EASY diskette	-	diskette
VIII-18	Figure of the drawings which should accompany the abstract	None	
VIII-19	Language of filing of the international application	English	
IX-1	Signature of applicant or agent		
IX-1-1	Name	STERNAGEL, FLEISCHER, GODEMEYER & PARTNER	
IX-1-2	Name of signatory	Dr. Holm Fleischer	
IX-1-3	Capacity	Representative (Association No. 144)	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	



Copy

4/4

PCT REQUEST

5807WO

Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	---	--



PCT (ANNEX - FEE CALCULATION SHEET)

5807WO

Original (for **SUBMISSION**) - printed on 17.08.2000 11:17:30 AM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only	
0-1	International Application No.	
0-2	Date stamp of the receiving Office	
0-4	Form - PCT/RO/101 (Annex) PCT Fee Calculation Sheet	
0-4-1	Prepared using	PCT-EASY Version 2.91 (updated 10.05.2000)
0-9	Applicant's or agent's file reference	5807WO
2	Applicant	BIOFRONTERA PHARMACEUTICALS GMBH, et al.
12	Calculation of prescribed fees	fee amount/multiplier total amounts (EUR)
12-1	Transmittal fee T	⇒ 102
12-2	Search fee S	⇒ 945
12-3	International fee Basic fee (first 30 sheets) b1	409
12-4	Remaining sheets	54
12-5	Additional amount (X)	9
12-6	Total additional amount b2	486
12-7	b1 + b2 = B	895
12-8	Designation fees Number of designations contained in international application	4
12-9	Number of designation fees payable (maximum 8)	4
12-10	Amount of designation fee (X)	88
12-11	Total designation fees D	352
12-12	PCT-EASY fee reduction R	-126
12-13	Total International fee (B+D-R) I	⇒ 1.121
12-14	Fee for priority document Number of priority documents requested	1
12-15	Fee per document (X)	30
12-16	Total priority document fee P	⇒ 30
12-17	TOTAL FEES PAYABLE (T+S+I+P)	⇒ 2.198
12-19	Mode of payment	authorization to charge deposit account
12-20	Deposit account instructions The receiving Office:	European Patent Office (EPO) (RO/EP)
12-20-1	is hereby authorized to charge the total fees indicated above to my deposit account	✓
12-20-2	is hereby authorized to charge any deficiency or credit any over-payment in the total fees indicated above to my deposit account	✓



Original (for **SUBMISSION**) - printed on 17.08.2000 11:17:30 AM**PCT-EASY INFORMATION SHEET**

(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG


Green?	States More designations could be made. The following States have not been designated: AP:(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW); EA:(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM); OA:(BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG); AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, LI, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW. Please verify.
Green?	Names Applicant 1.:Telephone No. missing
Green?	Applicant 1.:Facsimile No. missing
Yellow!	Contents The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
Green?	Fees Please confirm that fee schedule utilized is the latest available
Green?	Payment Please ensure that you have a valid deposit account with the receiving Office selected.

Before submitting the International Application, please carefully verify that:

- the information contained on printed Request form is correct;
- Box IX of the Request form and item 12-22 of the Annex to the Request form have been signed;
- all elements of the international application as indicated in Box VIII of the Request form have been attached; and,
- the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The attached PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must copy the submitted application as a template and make the change or correction in a new application (using the submitted application as a template). You may create such a template by copying the submitted application from the "Stored Forms" folder to the "New PCT Forms" folder. Open the new (.0WO) file created in the "New PCT Forms" folder, correct the errors and proceed with the submission process again.




Copy

PCT (ANNEX - FEE CALCULATION SHEET)


5807WO

Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

12-20-3	is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account	✓
12-21	Deposit account No	28 000 797
12-22	Date	17 August 2000 (17.08.2000)
12-23	Name and signature	STERNAGEL, FLEISCHER, GODEMEYER & PARTNER 

VALIDATION LOG AND REMARKS

13-2-2	Validation messages States	Green? More designations could be made. The following States have not been designated: AP:(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW); EA:(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM); OA:(BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG); AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, LI, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW. Please verify.
13-2-3	Validation messages Names	Green? Applicant 1.:Telephone No. missing
		Green? Applicant 1.:Facsimile No. missing
13-2-6	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
13-2-7	Validation messages Fees	Green? Please confirm that fee schedule utilized is the latest available
13-2-8	Validation messages Payment	Green? Please ensure that you have a valid deposit account with the receiving Office selected.



Original (for SUBMISSION) - printed on 17.08.2000 11:17:30 AM

PCT-EASY INFORMATION SHEET

(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG

Green?	States More designations could be made. The following States have not been designated: AP:(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW); EA:(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM); OA:(BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG); AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CH, LI, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW. Please verify.
Green?	Names Applicant 1.:Telephone No. missing
Green?	Applicant 1.:Facsimile No. missing
Yellow!	Contents The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
Green?	Fees Please confirm that fee schedule utilized is the latest available
Green?	Payment Please ensure that you have a valid deposit account with the receiving Office selected.

Before submitting the International Application, please carefully verify that:

- the information contained on printed Request form is correct;
- Box IX of the Request form and item 12-22 of the Annex to the Request form have been signed;
- all elements of the international application as indicated in Box VIII of the Request form have been attached; and,
- the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The attached PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must copy the submitted application as a template and make the change or correction in a new application (using the submitted application as a template). You may create such a template by copying the submitted application from the "Stored Forms" folder to the "New PCT Forms" folder. Open the new (.0WO) file created in the "New PCT Forms" folder, correct the errors and proceed with the submission process again.

PATENT COOPERATION TREATY

From the RECEIVING OFFICE

Sternagel, Fleischer,
Godemeyer & Partner

PCT

To:

STERNAGEL, FLEISCHER,
GODEMEYER & PARTNER
Braunsberger Feld 29
D-51429 Bergisch Gladbach
ALLEMAGNE

22. Sep. 2000

NOTIFICATION OF THE INTERNATIONAL
APPLICATION NUMBER AND OF THE
INTERNATIONAL FILING DATE

(PCT Rule 20.5(c))

Date of mailing
(day/month/year)

20. 09. 2000

Applicant's or agent's file reference
5807WO

IMPORTANT NOTIFICATION

International application No.
PCT/EP 00/08071

International filing date (day/month/year)
18/08/2000

Priority date (day/month/year)
30/08/1999

Applicant
BIOFRONTERA PHARMACEUTICALS GMBH

Title of the invention

1. The applicant is hereby notified that the international application has been accorded the international application number and the international filing date indicated above.
2. The applicant is further notified that the record copy of the international application was transmitted to the International Bureau on the above date of mailing.
3. ☐ Other:

* The International Bureau monitors the transmittal of the record copy by the receiving Office and will notify the applicant (with Form PCT/IB/301) of its receipt. Should the record copy not have been received by the expiration of 14 months from the priority date, the International Bureau will notify the applicant (Rule 22.1(c)).

Name and mailing address of the receiving Office




European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel.: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

N. MAILLIARD
Tel.: (070) 340.28.55
The Hague

N. Mailliar



PCT

Sternagel, Fleischer,
Godemeyer & Partner

07. März 2001

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

eingegangen/received

Applicant's or agent's file reference 5807W0	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 00/ 08071	International filing date (day/month/year) 18/08/2000	(Earliest) Priority Date (day/month/year) 30/08/1999
Applicant BIOFRONTERA PHARMACEUTICALS GMBH et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.




because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.



A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/12	C12N5/10	C12N1/21	C12N1/19	C07K14/47
	A01K67/027	A61K49/00	C12Q1/68		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A01K A61K C12O

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X L	<p>KESSLER J ET AL: "Investigation of the pathogenic mechanism of parkin mutations" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, pages 52-Abstract 27.20, XP000884113</p> <p>29th Annual Meeting of the Society for Neuroscience, Part 1, Miami Beach, Florida, USA, October 23-28, 1999</p> <p>-& DALIE J E (PROGRAM MANAGER - SOCIETY FOR NEUROSCIENCE): "Publication dates for the 1999 Abstract Volumes"</p> <p>SOCIETY FOR NEUROSCIENCE ABSTRACTS, 16 August 1999 (1999-08-16), XP002157614</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

27 February 2001


07/03/2001

Name and mailing address of the ISA

Authorized officer _____


European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Lonnoy, 0



C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication where appropriate of the relevant passages	Relevant to claim No.
Y	<p>DATABASE EMROD E.M.B.L. Databases; Accession Number: AB019558, 13 July 1999 (1999-07-13) SHIMIZU N ET AL: "Mus musculus mRNA for parkin, complete cds" XP002131476 cited in the application 100% identity in 1644 bp overlap with SeqIdNo.1 abstract</p> <p>---</p>	1-22
Y	<p>WO 98 59050 A (JOHNSON WILLIAM G ;LAVEDAN CHRISTIAN (US); NUSSBAUM ROBERT L (US);) 30 December 1998 (1998-12-30) claims 62,63</p> <p>---</p>	8-22
Y	<p>GOLDBERG M S ET AL: "STUDIES OF WILD-TYPE AND MUTANT ALPHA-SYNUCLEIN IN TRANSGENIC MICE" ANNUAL MEETING SOCIETY NEUROSCIENCE, XX, XX, vol. 24, no. 1/02, 1998, page 966 XP000884112 the whole document</p> <p>---</p>	8-22
Y	<p>KITADA ET AL: "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 392, no. 6676, 9 April 1998 (1998-04-09), pages 605-608, XP002108469 ISSN: 0028-0836 cited in the application figure 4C & WO 99 40191 A (SHIMIZU NOBUYOSHI ;MIZUNO YOSHIKUNI (JP)) 12 August 1999 (1999-08-12)</p> <p>---</p>	1-7
Y	<p>LÜCKING ET AL: "Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism" LANCET THE, GB, LANCET LIMITED. LONDON, vol. 352, no. 9137, 24 October 1998 (1998-10-24), pages 1355-1356, XP002108466 ISSN: 0140-6736 cited in the application the whole document</p> <p>---</p>	1-7
	-/--	



C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	<p>HATTORI ET AL: "Point Mutations (Thr240Arg and Ala311Stop) in the Parkin Gene"</p> <p>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 249, no. 3, 1998, pages 754-758, XP002108468</p> <p>ISSN: 0006-291X</p> <p>cited in the application</p> <p>figure 1</p> <p>---</p>	1-7
Y	<p>LEROY ET AL: "Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease"</p> <p>HUMAN GENETICS,DE,BERLIN, vol. 103, no. 4, October 1998 (1998-10), pages 424-427, XP002108470</p> <p>cited in the application</p> <p>figure 1</p> <p>---</p>	1-7
Y	<p>ABBAS ET AL: "A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe"</p> <p>HUMAN MOLECULAR GENETICS,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 8, no. 4, April 1999 (1999-04), pages 567-574, XP002108471</p> <p>ISSN: 0964-6906</p> <p>cited in the application</p> <p>the whole document</p> <p>---</p>	1-7
Y	<p>HATTORI N ET AL: "Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals"</p> <p>ANN NEUROL., vol. 44, no. 6, December 1998 (1998-12), pages 935-941, XP000877155</p> <p>cited in the application</p> <p>table 2</p> <p>---</p>	1-7
P,X	<p>WO 00 31253 A (INST NAT SANTE RECH MED ;BOULEY SANDRINE (FR); BRICE ALEXIS (FR);) 2 June 2000 (2000-06-02)</p> <p>claims 39,40</p> <p>-----</p>	1-22



INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08071

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9859050	A	30-12-1998	AU 8163798 A	04-01-1999
WO 0031253	A	02-06-2000	FR 2786199 A	26-05-2000
			FR 2797272 A	09-02-2001
			AU 1276900 A	13-06-2000

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:
 STERNAGEL, FLEISCHER,
 GODEMEYER & PARTNER
 Braunsberger Feld 29
 D-51429 Bergisch Gladbach
 GERMANY

**Sternagel, Fleischer,
 Gode Meyer & Partner**

07. März 2001

eingegangen/received

NOTIFICATION OF TRANSMITTAL OF
 THE INTERNATIONAL SEARCH REPORT
 OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing
 (day/month/year)

07/03/2001

Applicant's or agent's file reference

5807W0

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/EP 00/08071

International filing date
 (day/month/year)

18/08/2000

Applicant

BIOFRONTERA PHARMACEUTICALS GMBH et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.


Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
 NL-2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Carla Louro



NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.


What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.



NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged,
- (ii) the claim is cancelled,
- (iii) the claim is new,
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

